You are on page 1of 64

Final Programme

www.ccocr2010.org

We gratefully acknoWledge the generous support of our gracious supporters.

5th Canadian Conference on Ovarian Cancer Research

Table of Contents
2 3 5 5 9 10 11 12 13 13 17 27 40 49 52 Welcome to Toronto Committees Conference Objectives Conference Information About Toronto Useful Information Social Programme Instructions to Oral and Poster Presenters Invited Faculty Travel Awards Detailed Programme - Sunday, May 16 Detailed Programme - Monday, May 17 Detailed Programme - Tuesday, May 18 Index of Presenters Delegate Directory

www.ccocr2010.org

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

Welcome to Toronto
MESSAGE FROM THE CONFERENCE CO-CHAIRS

Dear colleagues, We welcome you to Toronto for the 5th Canadian Conference on Ovarian Cancer Research. This years conference is building upon the tremendous momentum generated by previous meetings of this group in Ottawa, Vancouver and Montral. Each conference builds on the vision of the conference founder, Dr. Barbara Vanderhyden, which is to offer a meeting for the multidisciplinary ovarian cancer research community in Canada. Along with the Society of Gynecologic Oncology of Canada (GOC) and Ovarian Cancer Canada (OCC), we invite you on a Journey to Discovery, Prevention and Cure, where we are featuring renowned Canadian and International researchers. Presentations range from biomarker discovery and validation, cells of origin and models of ovarian cancer to susceptibility, risk factors, novel therapies, to current and emerging clinical trials for ovarian cancer. Additional presentations on these themes were selected from the submitted abstracts. Two workshops provide an opportunity for the ovarian research community to exchange ideas and discuss the implications of its discoveries and next steps. The main conference is preceded by an interactive workshop for trainees, which was very successful at the last conference. A full-day workshop for survivors, their families and friends as well as caregivers is taking place in conjunction with the conference for the very first time. This meeting is a unique forum in which all ovarian cancer researchers, from scientists to clinicians, have the ability to present and discuss their work, forge new collaborations, or strengthen existing ones! Participate actively, find new collaborators and witness the capacity building of our growing community by inspiring graduate students and other learners to pursue their professional goals as researchers in ovarian cancer! Enjoy this conference! Michelle Letarte PhD Co-Chair CCOCR 2010 Mol. Structure & Function Program Hospital for Sick Children
2 Final Programme

Joan Murphy MD Co-Chair CCOCR 2010 Division of Gynaecologic Oncology UHN/Princess Margaret Hospital

Elisabeth Ross MHSc Honorary Co-Chair CCOCR 2010 Chief Executive Officer Ovarian Cancer Canada

Marie Plante MD President The Society of Gynecologic Oncology of Canada

5th Canadian Conference on Ovarian Cancer Research

Committees
LOCAL ORGANIZING COMMITTEE

Dr. Michelle Letarte, Ph.D., University of Toronto - Conference Co-Chair Dr. Joan Murphy, M.D., University of Toronto - Conference Co-Chair Ms. Elisabeth Ross, M.HSc., Chief Executive Officer, Ovarian Cancer Canada - Honorary Co-Chair Dr. Marcus Bernardini, M.D., University of Toronto Dr. Theodore Brown, Ph.D., University of Toronto Dr. Hal Hirte, M.D., McMaster University Dr. Thomas Kislinger, Ph.D., University of Toronto Dr. Amit Oza, M.D., University of Toronto Dr. Chun Peng, Ph.D., York University Dr. Jim Petrik, Ph.D., University of Guelph Dr. Barry Rosen, M.D., University of Toronto Dr. Trevor Shepherd, Ph.D., University of Western Ontario Dr. Brigitte Thriault, Ph.D., University of Toronto Dr. Alicia Tone, Ph.D., University of Toronto Dr. Johanne Weberpals, M.D., University of Ottawa Mr. Neil Winegarden, University of Toronto
NATIONAL ADVISORY COMMITTEE

Dr. David Huntsman, M.D., University of British Columbia Dr. Helen Mackay, M.D., Division of Hematology/Oncology, UHN, Princess Margaret Hospital Dr. Anne-Marie Mes-Masson, Ph.D., Universit de Montral Dr. Dianne Miller, M.D., Reproductive Endocrinology & Infertility, BC Women's Hospital Dr. Brad Nelson, Ph.D., BC Cancer Agency Dr. Diane Provencher, M.D., CHUM - Hpital Notre-Dame Dr. Jeremy Squire, Ph.D., Queens University Dr. Helen Steed, M.D., University of Alberta Dr. Barbara Vanderhyden, Ph.D., University of Ottawa

www.ccocr2010.org

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

ABSTRACT REVIEW COMMITTEE

Dr. Trevor Shepherd, Ph.D., University of Western Ontario - Chair Dr. Marcus Bernardini, M.D., University of Toronto Dr. Theodore Brown, Ph.D., University of Toronto Dr. Blaise Clarke, M.D., Genetic Pathology Evaluation Centre Dr. Thomas Kislinger, Ph.D., University of Toronto Dr. Michelle Letarte, Ph.D., University of Toronto Dr. Joan Murphy, M.D., University of Toronto Dr. Jim Petrik, Ph.D., University of Guelph Dr. Brigitte Thriault, Ph.D., University of Toronto
AWARD COMMITTEE

Dr. Jim Petrik, Ph.D., University of Guelph, Co-chair Dr. Trevor Shepherd, Ph.D., University of Western Ontario, Co-chair Dr. Marcus Bernardini, M.D., University of Toronto Dr. Gabriel DiMattia, Ph.D., London Regional Cancer Program, London Health Sciences Centre Dr. Jules Dor, Ph.D., Memorial University of Newfoundland Dr. Michelle Letarte, Ph.D., University of Toronto Dr. Dianne Miller, M.D., Reproductive Endocrinology & Infertility, BC Women's Hospital Dr. Brad Nelson, Ph.D., BC Cancer Agency

Final Programme

5th Canadian Conference on Ovarian Cancer Research

Conference Objectives
CCOCR has a broad mandate to cover all topics related to ovarian cancer including fundamental, translational, clinical, epidemiological, and psycho-social research. Participants include scientists, clinical researchers, graduate students, fellows and residents from across Canada. The objectives of the conference are: 1. to increase information dissemination and to promote identification of the most pressing questions in ovarian cancer, 2. to promote encounters and exchange of ideas between colleagues and trainees in basic and clinical areas, 3. to facilitate networking and collaboration across the country.

Conference Information
ABSTRACTS

All abstracts are available in the private section of the website as well as on the USB key.
BUSINESS CENTRE

A business centre is located in the main lobby area, next to the Delta Privileges desk. It will be able to handle your requests for photocopies, faxes, Internet access etc. Hours of operation are: Monday to Friday: 07:00 - 20:00; Saturday: 07:00 - 16:00; Sunday: 10:00 - 18:00.
CME CREDITS

Accreditation for this event is provided through The Society of Obstetricians and Gynaecologists of Canada (SOGC). This event is an accredited group learning activity under section 1 as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. (Programme number: 00274) The following credit hours can be claimed (one credit per hour): May 16 May 17 May 18 7 hours 7 hours 5 hours
www.ccocr2010.org 5

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

Delegates requiring CME Credits must sign in at the registration desk during the conference. An evaluation form is in your delegate bag. Please return it to the registration desk at the end of the conference. CME Certificates must be requested at the registration desk.
CONFERENCE EVALUATION

A Conference evaluation form is included in your delegate bag. Please complete it and drop it off at the registration desk. The committee appreciates your constructive feedback.
DELEGATE HOSPITALITY

A notepad and pen are included in your delegate bag for your convenience. Toronto maps and guidebooks are available at the registration desk.
ENVIRONMENTAL CONSIDERATIONS

We incorporated the following considerations into the planning of this conference: Online abstract review requiring no printing Online registration system requiring no printing E-mail marketing requiring no printing Water and juice pitchers instead of bottled drinks Reduction of print materials by posting abstracts online The hotel is a 4 green keys property, which means that it has shown national industry leadership and commitment to protecting the environment through wide ranging policies and practices. The hotel has mature programs in place that involve management, employees, guests, and the public, and which have shown substantial and measurable results.
EMERGENCY/FIRST AID

For any emergency or first aid services inside the Delta Chelsea Inn, please dial 0 for the operator from any available house phone.
INFORMATION

Should you require any assistance during the Conference, please call the Conference Services desk via the hotel operator at 416-595-1975. The Conference Services Desk will be located in the registration area and will be in service for the duration of the Conference.

Final Programme

5th Canadian Conference on Ovarian Cancer Research

INTERNET ACCESS

Computer stations are available to delegates. Wireless Internet is available in the lobby area as well as in the hotel restaurants.
LOST AND FOUND

Any lost and found items will be held at the Conference Services Desk for the duration of the event. For any unclaimed items after the Conference, please contact IS Event Solutions.
LUGGAGE

During the CCOCR conference, whether you are staying at the Hotel Delta Chelsea Inn or at a different hotel, you can leave your suitcases with the concierge. The conference organizers do not accept liability for any luggage left unattended and will not store any suitcases at the registration desk.
MEALS AND REFRESHMENTS

Coffee breaks will be served daily in the mornings and afternoons in Mountbatten Lane. For times of service, please refer to the detailed programme section. A continental breakfast will be available in the foyer area every morning. Please feel free to serve yourself before entering the morning session. Lunch will be served in Mountbatten Lane on Monday and Tuesday.
POSTER AREA AND POSTER SESSIONS

Posters are installed in Mountbatten Lane and will be on display for the duration of the conference. Door prices will be drawn at the end of each poster session. Poster sessions are scheduled as follows: Session I Session II May 16 17:00 - 20:00 May 17 11:30 - 13:30

Session III May 18 11:15 - 13:30


POSTER AWARDS & ORAL COMMUNICATION AWARDS

The review committee will visit posters of all trainees on the assigned days. Presenters shall thus make sure to be present at their poster at the time indicated on the confirmation letter. The poster award winners as well as oral communication award winners will be announced at the closing session. Please plan on staying until the end of that session.

www.ccocr2010.org

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

PUBLIC NOTICE

The Hotel specifically and all Ontario public spaces in general are smoke-free environments. Smoking is permitted only outside of buildings.
REGISTRATION

For identification and security purposes, delegates must wear their name badges when onsite at the Delta Chelsea Inn Hotel.
REGISTRATION & INFORMATION DESK HOURS

Saturday, May 15 Sunday, May 16 Monday, May 17 Tuesday, May 18


TOURS

12:00 - 13:00 08:30 - 09:15 11:00 - 17:00 08:00 - 17:30 08:00 - 17:00

registration Trainee Day (MaRS TMDT4-204) registration Survivorship 2010 (Seymour) registration Conference (Mountbatten) registration Conference (Mountbatten) registration Conference (Mountbatten)

Should you be interested in obtaining information on guided tours, please make arrangements with the concierge at the hotel.

Final Programme

5th Canadian Conference on Ovarian Cancer Research

About Toronto
The city of Toronto boasts a population of more than 2.5 million people and 630 square kilometers, extending to almost 6 million people and more than 10 times the area in Greater Toronto. Toronto is Canadas major financial centre and enjoys a diverse population with many cultures integrated into its colourful fabric. The city is nestled around Toronto Harbour, has an above- and below-ground transit system and PATH, 27 kilometres of underground walkways linking shopping, services and entertainment! Toronto is packed with activities and events, so that there really is something for everyone. What comes to mind immediately is the CN Tower, Casa Loma, Ontario Place and the Toronto Zoo. And then theres the Distillery District, with galleries and restaurants, and a taste of the past at the Mackenzie House & Recreated Print Shop and Historic Fort York. Theatre fare ranges from Frankenstein to Jersey Boys and Mamma Mia, while the Canadian Opera Company boasts The Flying Dutchman and Mozarts Idomeneo. HarbourFront houses dance, art exhibits, dining and shopping, cruises, and nearby ferries to the Toronto Islands, allowing you to picnic, dine or enjoy a little bit of nature. Toronto has many and varied museums, where you can find dinosaurs and bat caves and then go on to Wedgewood, coffee and smokes in medieval Yemen, and east Asian paintings, all at the Royal Ontario Museum (ROM). Specialty museums include the Ceramics Museum, exhibiting Family Matters: Love, Marriage and Maiolica in the Italian Renaissance, the Textile Museum, with the Fashionably Wrapped: The Influence of Kashmir Shawls exhibit and the Bata Shoe Museums exhibit of On a Pedestal: From Renaissance Chopines to Baroque Heels. And, of course, theres always the Hockey Hall of Fame! Art runs the gamut, from Rembrandt/Freud etchings from life at the Art Gallery of Ontario (AGO) to suspended recycling-turned art, as in Katharine Harvey: Above and Below Exhibition downtown. And you can always head a little bit north to see an IMAX film showing the Grand Canyon: River At Risk and all the interactive exhibits at the Ontario Science Centre. If youre not sure where to go, you can take a tour, such as the free Tour Guys Walking Tours to the downtown old historic centre or to one of Torontos many colourful neighbourhoods, with a Chinatown and Kensington Market Tour. In short, there is a lot to see and do all you need is a little bit of time For whats on in Toronto, please go to http://www.toronto.ca/
www.ccocr2010.org 9

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

Useful Information
Climate Long, bright, sunny days are expected at this time of year in Toronto. Average daytime high temperatures are in the low 20s C (low 70s F), while evening temperatures can be as low as 10 C (50 F). A sports jacket or light coat is recommended. The meeting facilities and guest rooms are equipped with air conditioning. Credit Cards In order to report lost or stolen credit cards, these numbers will provide assistance. American Express 1-800-268-9805 Mastercard Visa 1-800-263-2263 1-800-847-2911

Dress Code The dress code during the conference is casual. Business-casual will be appreciated at the evening event. Getting Around Toronto Explore Toronto on one of North Americas finest transportation systems the Toronto Transit Commission (TTC). With easy-to-navigate subways, buses and streetcars, getting around the city is a snap. When using the TTC, a single fare will take you anywhere in the city on a one way trip. You can freely transfer between subway, streetcar and bus, but make sure you obtain a transfer when and where you pay your fare. On buses and streetcars, exact change is required. GO Transit is Ontarios inter-regional bus and train service. It links Toronto with outlying areas of the Greater Toronto and beyond. GO Trains and buses depart from Torontos Union Station at regular intervals throughout the day.

10

Final Programme

5th Canadian Conference on Ovarian Cancer Research

Social Programme
SUNDAY, MAY 16

Opening Reception 17:00 to 20:00 Hotel Delta Chelsea Inn, Mountbatten Lane (included in full registration fee for all participants) Dress Code: Casual An exciting evening awaits as the Conference officially opens with appetizers and beverages. Come and network with your colleagues to set the tone for the meeting. The first poster session of the Conference will take place at the same time! Exciting door prizes await!
MONDAY, MAY 17

Social Evening 19:00 to 23:00 Cooperage Space, Distillery District, 55 Mill Street, Building 32 (pre-reservation fee of $25 if reserved pre-conference; each additional guest ticket costs $85) Dress Code: Business-casual Spend a nice spring evening with your colleagues in one of Toronto's trendiest and hippest neighbourhoods, the Distillery District. This fun evening of networking will touch on all your senses: internationally acclaimed contemporary Qubec artwork, authentic Toronto food fare, delicious Ontario wines and outstanding artisan cheeses all of this in a gorgeous backdrop of exposed brick and original plaster walls.
WALKING DIRECTIONS (ABOUT 30 MIN)

- Turn right on Gerrard, then right on Yonge Street. - Walk down Yonge Street to King Street. - Turn left on King Street, going East. - Turn right on Parliament Street, then left on Mill Street. - Enter through the gates of the main entrance to the Distillery District. Building 32 is on your right.
TAXI (ABOUT 10 MIN, $10-12 EACH WAY)

PUBLIC TRANSPORTATION (ABOUT 15 MIN; $3 EXACT CHANGE OR TOKEN OR TICKET)

- Take subway service from College (corner of Yonge and College.) - Take direction Downsview get off at King. - Take the Streetcar from King and Yonge (line 504) to King and Parliament. - Walk South on Parliament Street, turn left on Mill Street, enter through the gates at 55 Mill Street. The Cooperage Space is in building 32, on your right.
www.ccocr2010.org 11

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

Instructions for Oral Abstract Presenters


Speakers must check-in and submit their PowerPoint presentation at least three hours prior to their presentation. We have assigned two computers for presenters to upload and preview their slides. These computers are installed in the registration area and are networked with the main session computer. You will be required to provide your presentation on USB key or CD. The AV technician will review your slides with you to ensure that all fonts and videos are functional. We will then keep one copy of your PPT file on the computer and send it to the session room computer. Please check-in with the technician in the meeting room half hour before your session to verify your presentation one last time, review slide advancement, etc. Please note that all presentations will be deleted from all computers at the end of the day. INDIVIDUAL LAPTOP COMPUTERS ARE NOT PERMITTED FOR PRESENTATIONS!

Instructions for Poster Presenters


Poster presenters should mount their posters in the designated poster area (Mountbatten Lane) between 11:00-17:00 on Sunday, May 16 and remove no later than 17:30 on Tuesday, May 18. Conference staff is available at the registration desk. Velcro will already be attached to your board when you arrive. Any posters that are not taken down by 17:30 on Tuesday, May 18 will be taken down by conference staff. Posters unclaimed by 18:00 on Tuesday, May 18 will be discarded.

12

Final Programme

5th Canadian Conference on Ovarian Cancer Research

Invited Faculty
Dr. Alan Ashworth, Institute of Cancer Research, London, UK Dr. Patrick O. Brown, Stanford University, Stanford, CA, USA Dr. Denise C. Connolly, Fox Chase Cancer Center, Philadelphia, PA, USA Dr. Christopher Crum, Brigham and Women's Hospital, Boston, MA, USA Dr. Janet Dancey, National Cancer Institute of Canada, Kingston; High Impact Clinical Trials Program, OICR, Toronto, ON, Canada Dr. John E. Dick, University Health Network, Toronto, ON, Canada Dr. David Huntsman, University of British Columbia, Vancouver, BC, Canada Dr. Robert S. Kerbel, Sunnybrook Health Sciences Centre, Toronto, ON, Canada Dr. Thomas Kislinger, University Health Network, Toronto, ON, Canada Dr. Elise C. Kohn, National Cancer Institute, Bethesda, MD, USA Dr. Steven Narod, University of Toronto, Toronto, ON, Canada Dr. Jim Petrik, University of Guelph, Guelph, ON, Canada

Travel Awards
The travel awards programme is funded by the Canadian Cancer Society Research Institute and the Princess Margaret Hospital Foundation via a Sue Bernier Award. The following individuals have been selected for a travel award due to their outstanding abstract quality. Mohammad Reza Abedini, Departments of Obstetrics & Gynaecology and Cellular & Molecular Medicine, University of Ottawa; Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada Vronique Barrs, Institut du Cancer de Montral/CR-CHUM, Montral, QC, Canada Jung-Chien Cheng, Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada Rohann Correa, Translational Ovarian Cancer Research Program, London Regional Cancer Centre; Department of Biochemistry, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada
www.ccocr2010.org 13

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

Bojana Djordjevic, Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA Thuy-Vy Do, Womens Cancer Program, Fox Chase Cancer Center, Philadelphia, PA, USA Nadzeya Goncharenko-Khaider, Microbiologie et Infectiologie, Universit de Sherbrooke, Sherbrooke, QC, Canada Ursula Kortmann, Department of Pathology and Laboratory Medicine, University of British Columbia; Living Tumor Laboratory, BC Cancer Agency; Vancouver, BC, Canada Man-Tat Lau, Department of Obstetrics and Gynecology, Child and Family Research Institute, University of British Columbia, Vancouver, BC, Canada Takayo Ota, Department of Experimental Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA Teresa Peart, Translational Ovarian Cancer Research Program, London Regional Cancer Program; Department of Anatomy and Cell Biology, The University of Western Ontario; London, ON, Canada Sara Rafferty, Department of Cellular and Molecular Medicine, University of Ottawa; Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada Kerri N. Smith, Division of BioMedical Sciences, Faculty of Medicine, Memorial University, St. Johns, NL, Canada Dominique Trudel, Department of Pathology & Cancer Research Center, Centre Hospitalier Universitaire de Qubec, Montral, QC, Canada Lisa Turchet, Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa; Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada Heidi Wells, Division of BioMedical Sciences, Faculty of Medicine, Memorial University, St. Johns, NL, Canada

14

Final Programme

5th Canadian Conference on Ovarian Cancer Research

SUNDAY, MAY 16 14:00 - 17:00 WELCOME REMARKS / SYMPOSIUM I GENOMICS AND PROTEOMICS IN THE DISCOVERY OF NOVEL BIOMARKERS AND THERAPIES
Co-Chairs: Anne-Marie Mes-Masson, Institut du Cancer de Montral, Montral, QC, Canada. Johanne Weberpals, Ottawa Health Research Institute, Ottawa, ON, Canada. This is an area of extensive research with the goal of identifying specific biomarkers for early detection of ovarian cancer. Dr. Patrick Brown is a world leader in this area and among other contributions has developed models to study the natural history of serous ovarian cancer in BRCA1 carriers to guide the rational design of an early detection strategy. Dr. David Huntsman is a pathologist actively involved in the International Cancer Genome Consortium (ICGC) who will report on his study of the genome in at least 50 ovarian tumors. This international effort is aimed at identifying genomic changes in ovarian cancers that may lead us to a more relevant classification of tumors and to novel biomarkers. Dr. Thomas Kislinger is studying the proteome of ovarian cancer cells with the aim of defining molecular signatures and potential early, pre-clinical markers of disease. Dr. Alan Ashworth contributed to the discovery of the BRCA2 gene and identified the exquisite sensitivity of BRCA1 or BRCA2 mutant cells to PARP inhibitors. Dr. Ashworths interests also include high-throughput genomic and functional approaches to the study of cancer.

14:00 - 14:30

THE PRE-DIAGNOSIS NATURAL HISTORY OF OVARIAN CANCER AND ITS IMPLICATIONS FOR EARLY DETECTION
Patrick O. Brown, Stanford University, Stanford, CA, USA.

14:30 - 15:00

DECODING OVARIAN CANCER: ONE SUBTYPE AT A TIME


David Huntsman, University of British Columbia, Vancouver, BC, Canada.

www.ccocr2010.org

17

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

SUNDAY, MAY 16 15:00 - 15:15 TUMOUR TYPE IS AN IMPORTANT DETERMINANT OF ONCOPROTEIN SIGNALING EXPRESSION IN OVARIAN CANCER
Mark S. Carey1, Bryan T. Hennessy7, Roshan Agarwal2, C. Blake Gilks3, Kenneth D. Swenerton4, Steve E. Kalloger5, Dianne Miller1, David G. Hunstman6, Gordon B. Mills8. 1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of British Columbia; 2Department of Oncology, Hammersmith Hospital Campus, Imperial College, UK; 3Department of Pathology, Vancouver Coastal Health and University of British Columbia; 4Department of Medical Oncology and the Cheryl Brown Ovarian Cancer Outcomes Unit, British Columbia Cancer Agency, Vancouver, BC; 5Genetic Pathology Evaluation Centre of the Prostate Research Center, Vancouver, BC; 6Department of Pathology and Hereditary Cancer Program, Vancouver Coastal Health and British Columbia Cancer Agency; 7Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland; 8 Department of Systems Biology, M.D. Anderson Cancer Center, University of Texas, Houston, TX, USA.

15:15 - 15:45 15:45 - 16:15

COFFEE BREAK OVARIAN CANCER BIOMARKER DISCOVERY BY MS-BASED PROTEOMICS


Thomas Kislinger, University Health Network, Toronto, ON, Canada.

18

Final Programme

5th Canadian Conference on Ovarian Cancer Research

SUNDAY, MAY 16 16:15 - 16:30 CLEAR CELL AND MUCINOUS EPITHELIAL OVARIAN CANCERS EXHIBIT HIGH LEVELS OF HYALURONIDASE-1 WHICH INVERSELY CORRELATE WITH THE EXPRESSION OF ESTROGEN RECEPTOR ALPHA AND PROGESTERONE RECEPTOR
Euridice Carmona1,2, Paule Hlna Yoffou1, Liliane Meunier4, Lydia Edjekouane1, Diane M. Provencher3,4, Anne-Marie Mes-Masson2,4. 1 Maisonneuve-Rosemont Hospital Research Center; 2Department of Medicine, University of Montral; 3Department of Obstetrics & Gynecology, University of Montral; 4CHUM Research Center / Institut du Cancer de Montral; Montral, QC, Canada.

16:30 - 17:00

SYNTHETIC LETHAL APPROACHES TO CANCER THERAPY


Alan Ashworth, Institute of Cancer Research, London, UK.

17:00 - 20:00

OPENING RECEPTION AND POSTER SESSION I


Please refer to page 11 for details.

P.02

FOXL2 IMMUNOSTAINING IS A SENSITIVE DIAGNOSTIC MARKER FOR OVARIAN SEX CORD-STROMAL TUMORS OM Al-Agha1, SE Kalloger1, DG Huntsman1, RH Young2, CB Gilks1. 1 Center for Translational and Applied Genomics, British Columbia Cancer Agency and Genetic Pathology Evaluation Centre, Vancouver General Hospital, Vancouver, BC, Canada; 2Department of Pathology, Massachusetts General Hospital, Boston, MA, USA. RETINOBLASTOMA (RB) PATHWAY ABROGATION IS CHARACTERISTIC OF EARLY EVENTS IN HIGH GRADE SEROUS OVARIAN CARCINOMA Anca Milea, Sophia George, Heather Begley, Patricia Shaw. Department of Pathology, University Health Network, Toronto, ON, Canada.

P.04

www.ccocr2010.org

19

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

SUNDAY, MAY 16
P.06 THE ROLE OF MMP14 EXPRESSION IN THE PROGNOSIS OF WOMEN WITH OVARIAN CANCER Dominique Trudel1,2, Ion Popa1, Bernard Ttu1,2, lodie Samson2, Isabelle Bairati2. 1Department of Pathology, Centre Hospitalier Universitaire de Qubec; 2Cancer Research Center, Centre Hospitalier Universitaire de Qubec, Montral, QC, Canada. THE INVOLVEMENT OF RAN IN OVARIAN CANCER PROGRESSION Katia Y. Caceres1, Vronique Barrs1, Jason Madore1, Cristina Storoz1, Patricia N. Tonin2, Diane M. Provencher1, Anne-Marie Mes-Masson1. 1Institut du Cancer de Montral / Centre de recherche du Centre hospitalier de lUniversit de Montral (CRCHUM); 2The Research Institute of the McGill University Health Centre (RI-MUHC); Montral, QC, Canada. MICRORNAS AS BIOMARKERS FOR EARLY DETECTION OF HIGH GRADE SEROUS CARCINOMA OF THE OVARY Ursula Kortmann1,2, Akira Watahiki2, Cheng-Han Lee3, Steve E Kalloger2, Jessica N McAlpine5, C Blake Gilks1,3,4, David G Huntsman1,4, Yuzhuo Wang2,6. 1Department of Pathology and Laboratory Medicine, University of British Columbia; 2Living Tumor Laboratory, BC Cancer Agency; 3Department of Pathology, Vancouver General Hospital; 4Center for Translational and Applied Genomics, BC Cancer Agency; 5Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of British Columbia; 6The Prostate Centre at Vancouver General Hospital and Department of Urologic Sciences, University of British Columbia; Vancouver, BC, Canada. INVESTIGATING BIOMARKERS FOR THE EARLY DETECTION OF OVARIAN CANCER Joshua Durbin1,4, Guo Xiong Xu1, Despina Voulgaraki1, Thomas Kislinger4, Theodore Brown2,3, Michelle Letarte1,3,4. 1Molecular Structure and Function, Hospital for Sick Children; 2Department of Physiology, University of Toronto; 3Department of Obstetrics and Gynecology, University of Toronto; 4Department of Medical Biophysics, University of Toronto; Toronto, ON, Canada.

P.09

P.12

P.14

20

Final Programme

5th Canadian Conference on Ovarian Cancer Research

SUNDAY, MAY 16
P.17 INTEGRATIVE GENOMIC ANALYSIS OF CHEMORESISTANCE BIOMARKERS IN OVARIAN CANCER CELL LINES Alexandria Haslehurst, Harriet Feilotter, Jeremy Squire. Department of Pathology and Molecular Medicine, Queens University, Kingston, ON, Canada. IDENTIFICATION OF GRADE-SPECIFIC ALTERNATIVE SPLICING EVENTS IN SEROUS OVARIAN TUMOURS Roscoe Klinck1,2, Panagiotis Prinos1, Mathieu Durand1, Philippe Thibault1, Elvy Lapointe1, Hanad Nwilati1, Benoit Chabot1,2, Sherif Abou Elela1,2. 1Laboratoire de gnomique fonctionnelle, Facult de mdecine, Universit de Sherbrooke; 2Dpartement de microbiologie et dinfectiologie, Facult de mdecine, Universit de Sherbrooke; Sherbrooke, QC, Canada. SPLICE-SENSITIVE MOLECULAR SIGNATURE OF CHEMOSENSITIVITY IN ADVANCED SEROUS OVARIAN CANCER Jean-Philippe Brosseau1, Jean-Francois Lucier1, Hanad Nwilati1, Philippe Thibault1, Roscoe Klinck1, Dimcho Bachvarov2, JeanPierre Perreault1, Sherif Abou Elela1. 1Groupe ARN, Laboratoire de Gnomique Fonctionnelle, Facult de mdecine et des sciences de la sant, Universit de Sherbrooke, Sherbrooke; 2Laboratoire Oncognomique, Universit Laval, CHUQ-Centre de recherche LHtel-Dieu de Qubec, Qubec; QC, Canada. IDENTIFICATION OF NOVEL DIAGNOSTIC AND PROGNOSTIC BIOMARKERS FOR SEROUS EPITHELIAL OVARIAN CANCER USING INTEGRATIVE MOLECULAR PROFILING Madhuri Koti, Paul Park, Paulo Nuin, Harreit Feilotter, Alexandria Haslehurst, Ricardo Vidal, Jeremy Squire. Department of Pathology and Molecular Medicine, Queens University, Kingston, ON, Canada.

P.21

P.24

P.26

www.ccocr2010.org

21

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

SUNDAY, MAY 16
P.29 EXPRESSION OF ESTROGEN RECEPTORS IN OVARIAN EPITHELIAL TUMORS OF MEXICAN WOMEN Mara del Carmen Mndez1, Marlon De Ita1, Vernica DazHernndez1, Maria Jos Gmora1, Flavia Morales-Vsquez2, Vernica Rodrguez-Mata3, Enrique Pedernera1. 1Departamento de Embriolgoa, Facultad de Medicina, Universidad Nacional Autnoma de Mxico; 2Oncologa Mdica, Instituto Nacional de Cancerologa; 3Departamento de Biolga Celular y Tisular, Universidad Nacional Autnoma de Mxico; Cd. de Mxico, D.F. Mxico. IDENTIFICATION OF MICRORNA SIGNATURES IN HUMAN AGING OVARIAN CANCER Shiying Cui, Yanfang Ding, Yue Du, Jinyao Zhao, Bin Liu, G. Guo. Department of Histology and Embryology, Dalian Medical University, Dalian, Liaoning, China. N-GLYCOSYLATION PATTERNS OF KALLIKREIN 6 IN OVARIAN CANCER Uros Kuzmanov1,2, Christopher R. Smith3, Antoninus Soosaipillai2, Eleftherios P. Diamandis1,2,3. 1Department of Laboratory Medicine and Pathobiology, University of Toronto; 2Department of Pathology and Laboratory Medicine, Mount Sinai Hospital; 3 Department of Clinical Biochemistry, University Health Network; Toronto, ON, Canada. REACTOME: A PATHWAY DATABASE AND A RESOURCE FOR INTERPRETING GENOMIC AND PROTEOMIC CANCER DATASETS Robin Haw1, Reactome Team1,2,3,4,5, Lincoln Stein1,2. 1Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON, Canada; 2Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA; 3European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK; 4St. Johns University, Queens, NY, USA; 5NYU School of Medicine, New York, NY, USA.

P.32

P.34

P.37

22

Final Programme

5th Canadian Conference on Ovarian Cancer Research

SUNDAY, MAY 16
P.41 FUNCTIONAL INTERACTION NETWORK-BASED APPROACH IN ANALYSIS OF THE ALTERED CANCER GENES Irina Kalatskaya, Guanming Wu, Robin Haw, Lincoln Stein. Informatics and Biocomputing, OICR, Toronto, ON, Canada. ESTABLISHING A FUNCTIONAL GENOMIC SIGNATURE OF SEROUS OVARIAN CANCER FOR THE IDENTIFICATION OF GENES ESSENTIAL FOR CANCER CELL PROLIFERATION AND SURVIVAL Mauricio A. Medrano1,2, Fernando S. Saiz1, Josee Normand1, Lakshmi Muthuswamy3, Troy Ketela7, Jason Moffat4,7, Robert Rottapel1,2,5,6,8. 1Ontario Cancer Institute, Department of Stem Cell and Developmental Biology, University of Toronto; 2Department of Medical Biophysics, Faculty of Medicine, University of Toronto; 3 Ontario Institute for Cancer Research, Informatics and Biocomputing Platform; 4Department of Molecular Genetics, Banting & Best Department of Medical Research, University of Toronto; 5 Department of Immunology, University of Toronto; 6Department of Medicine, University of Toronto; 7Terrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto; 8St. Michaels Hospital; Toronto, ON, Canada. OVER 80% OF HIGH-GRADE SEROUS OVARIAN CANCERS HARBOUR SOMATIC INACTIVATING MUTATIONS IN TP53 Suzanna L Arcand1, Michael C J Quinn2, Diane Provencher3,4, Anne-Marie Mes-Masson3,5, Patricia N Tonin1,2,6. 1The Research Institute of the McGill University Health Centre; 2Department of Human Genetics, McGill University; 3Centre de Recherche du Centre hospitalier de lUniversit de Montral/Institut du Cancer de Montral; 4Dpartement dObsttrique et Gyncologie, Division of Gynecologic Oncology, Universit de Montral; 5Dpartement de Mdicine, Universit de Montral; 6Department of Medicine, McGill University; Montral, QC, Canada.

P.45

P.47

www.ccocr2010.org

23

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

SUNDAY, MAY 16
P.49 CHROMOSOME X AND OVARIAN PHENOTYPES REVEALED THROUGH A MODEL OF SPONTANEOUS JUVENILE-ONSET GRANULOSA CELL TUMOURIGENESIS Heidi Wells1, Heather Young1, Kathy Shultz2, Wesley Beamer2, Ann Dorward1. 1Division of BioMedical Sciences, Faculty of Medicine, Memorial University, St. Johns, NL, Canada; 2The Jackson Laboratory, Bar Harbor, ME, USA. COMPARATIVE GENE EXPRESSION AND GENOMIC ANALYSIS OF LONG-TERM PASSAGES DERIVED FROM OVARIAN SEROUS CANCER SAMPLES FROM PRE- AND POST-CHEMOTHERAPY PATIENTS Michael Quinn1, Sohrab Shah6, Ali Heravi-Moussavi6, Suzanna Arcand2, Lu-Lin Wang3, Isabelle Ltourneau3, Diane Provencher4,5, Patricia Tonin1,2, David Huntsman6, Anne-Marie Mes-Masson3,4. 1 Department of Human Genetics, McGill University, Montral, QC; 2 The Research Institute of the McGill University Health Centre, Montral, QC; 3Centre de Recherche du Centre hospitalier de lUniversit de Montral/Institut du Cancer de Montral, Montral, QC; 4Dpartement de Mdicine, Universit de Montral, Montral, QC; 5Dpartement d Obsttrique et Gyncologie, Division of Gynecologic Oncology, Universit de Montral, Montral, QC; 6BC Ovarian Cancer Research Program, BC Cancer Agency, Vancouver, BC, Canada. WHOLE GENOME SNP ANALYSES OF EPITHELIAL OVARIAN TUMOURS IDENTIFY CHROMOSOMAL ABERRATIONS IN BENIGN, LOW MALIGNANT POTENTIAL AND LOW GRADE TUMOURS OF THE SEROUS SUBTYPE Ashley Birch1, Suzanna Arcand2, Diane Provencher3,4, Anne-Marie Mes-Masson3,5, Patricia Tonin1,2,6. 1Department of Human Genetics, McGill University; 2The Research Institute of the McGill University Health Centre; 3Centre de Recherche du Centre Hospitalier de lUniversit de Montral (CHUM), Institut du Cancer de Montral; 4Division of Gynecologic Oncology, Universit de Montral; 5Department of Medicine, Universit de Montral; 6 Department of Medicine, McGill University; Montral, QC, Canada.

P.53

P.55

24

Final Programme

5th Canadian Conference on Ovarian Cancer Research

SUNDAY, MAY 16
P.57 INTEGRATED GENOMIC, MICRORNA (MIRNA) AND PROTEOMIC PROFILING OF OVARIAN CARCINOMA Jane Bayani1,2, Uros Kuzmanov1,2, Ihor Batruch3, Paula Marrano4, Cassandra Graham1,4, Ralf Butzow5, Dionyssios Katsaros6, Yingye Zheng7, Jeremy Squire8, Eleftherios Diamandis1,2,3. 1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; 2Samuel Lunenfeld Research Institute, Joseph and Wolf Lebovic Health Centre and Mt. Sinai Hospital, Toronto, ON, Canada; 3Department of Clinical Biochemistry, Toronto General Hospital, University Health Network, Toronto, ON, Canada; 4Department of Laboratory Medicine and Pathobiology, Hospital for Sick Children, Toronto, ON, Canada; 5Department of Pathology University of Helsinki, Helsinki, Finland; 6Dip. Di Discipline Ostetriche e Genecologiche, University of Turin, Turin, Italy; 7Department of Biostatistics and Biomathematics, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 8 Department of Laboratory Medicine and Pathobiology, Queens University, Kingston, ON, Canada. AN INTEGRATED BIOMARKER DISCOVERY PLATFORM FOR OVARIAN CANCER Vathany Kulasingam1,2, Eleftherios P. Diamandis1,2,3. 1Department of Laboratory Medicine and Pathobiology, University of Toronto; 2 Department of Pathology and Laboratory Medicine, Mount Sinai Hospital; 3Department of Clinical Biochemistry, University Health Network; Toronto, ON, Canada. DISCOVERY AND TARGETED PROTEOMICS OF OVARIAN CANCER ASCITES: SYSTEMATIC ASSAY DEVELOPMENT FOR BIOMARKER QUANTIFICATION Sarah Elschenbroich1, Vladimir Ignatchenko1, Igor Jurisica1, Patricia A. Shaw2, Thomas Kislinger1. 1Department of Medical Biophysics, Ontario Cancer Institute; 2Department of Laboratory Medicine and Pathology; University of Toronto, Toronto, ON, Canada.

P.64

P.66

www.ccocr2010.org

25

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

SUNDAY, MAY 16
P.68 OVARIAN TUMOUR-ASSOCIATED SPLICE VARIANTS PROMOTE CELL SURVIVAL Panagiotis Prinos, Daniel Garneau, Marianne Boivin, Gendron Daniel, Lucier Jean-Franois, Jean-Philippe Brosseau, Karine Tremblay, Benoit Chabot, Raymund Wellinger, Sherif Abou-Elela. Laboratoire de gnomique fonctionnelle de lUniversit de Sherbrooke, Dpartement de microbiologie et dinfectiologie, Facult de mdecine et des sciences de la sant, Universit de Sherbrooke, Sherbrooke, QC, Canada. DEVELOPMENT OF CARBOPLATIN, DOCETAXEL, AND COMBINED CARBOPLATIN/DOCETAXEL DRUG RESISTANT OVARIAN CANCER CELL LINES Carita Lanner1,2, Stephen Armstrong1, Baoqing Guo3, Amadeo Parissenti1,2,3 1 Laurentian University; 2Northern Ontario School of Medicine, 3 Sudbury Regional Cancer Centre; Sudbury, ON, Canada

P.69

26

Final Programme

5th Canadian Conference on Ovarian Cancer Research

MONDAY, MAY 17 07:30 - 08:30 08:30 - 11:30 BREAKFAST SYMPOSIUM II: ETIOLOGY AND PREVENTION CELLS OF ORIGIN AND STEM CELLS
Co-Chairs: John McLaughlin, Cancer Care Ontario, Toronto, ON, Canada. Barbara Vanderhyden, University of Ottawa, Ottawa, ON, Canada. The ultimate goal of the ovarian cancer research community is prevention. In order to address that goal, discovering and understanding early molecular events, genetic predispositions and epigenetic influences and the role of stem cells in tumorigenesis and tumor behaviour are fundamental. In this symposium, Drs. Crum, Narod and Dick, all luminaries in their respective areas, will present the most current data and novel concepts that will inform and stimulate the participants and lead us to a fruitful discussion period.

08:30 - 09:00

STEM CELL BIOLOGY RENEWS CANCER RESEARCH


John E. Dick, University Health Network, Toronto, ON, Canada.

09:00 - 09:15

STEM CELL ANTIGEN-1 EXPRESSION MARKS A POPULATION OF MOUSE OVARIAN SURFACE EPITHELIAL CELLS WITH ENHANCED STEM/PROGENITOR CELL CHARACTERISTICS WHOSE SIZE IS REGULATED BY BRCA1 EXPRESSION
Lisa Turchet1,2, Olga Collins2, Barbara Vanderhyden1,2,3. 1 Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa; 2Centre for Cancer Therapeutics, Ottawa Hospital Research Institute; 3Department of Obstetrics and Gynecology, Faculty of Medicine, University of Ottawa; Ottawa, ON, Canada.

www.ccocr2010.org

27

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

MONDAY, MAY 17 09:15 - 09:30 CANCER-INITIATING CELLS IN SEROUS OVARIAN CANCER ARE RARE, BUT PHENOTYPICALLY HETEROGENEOUS
Jocelyn Stewart1,2, Patricia Shaw3, Marcus Bernardini4, Craig Gedye2, Laurie Ailles1,2, Benjamin Neel1,2. 1Department of Medical Biophysics, University of Toronto; 2Department of Stem Cell and Developmental Biology, Ontario Cancer Institute; 3Department of Pathology, University Health Network; 4Department of Gynecologic Oncology, University Health Network; Toronto, ON, Canada.

09:30 - 10:00

THE DISTAL FALLOPIAN TUBE: A NEW PARADIGM FOR SEROUS CARCINOGENESIS


Christopher Crum, Brigham & Womens Hospital, Boston, MA, USA.

10:00 - 10:30 10:30 - 10:45

COFFEE BREAK DAB2 ENHANCES GLUCOCORTICOID RECEPTOR-MEDIATED ANTI-INFLAMMATORY SIGNALLING IN ES2 OVARIAN CANCER CELLS
Alicia Tone1,2,3, Carl Virtanen5, Patricia Shaw2,3,4, Theodore J. Brown1,3. 1The Samuel Lunenfeld Research Institute, Mount Sinai Hospital; 2Dept. of Laboratory Medicine and Pathobiology, University of Toronto; 3Dept. of Obstetrics and Gynecology, University of Toronto; 4Dept of Pathology, University Health Network; 5Microarray Center, University Health Network; Toronto, ON, Canada.

10:45 - 11:15

INHERITED SUSCEPTIBILITY TO OVARIAN CANCER: CLINICAL AND PUBLIC HEALTH IMPLICATIONS


Steven Narod, University of Toronto, Toronto, ON, Canada.

28

Final Programme

5th Canadian Conference on Ovarian Cancer Research

MONDAY, MAY 17 11:15 - 11:30 THE CLINICAL PROFILE OF OVARIAN CANCER IN WOMEN WITH MSH2 LYNCH SYNDROME MUTATION IN NEWFOUNDLAND
Lesa Dawson1, Jane Green2, Roger Green2, Susan Stuckless3, Elizabeth Dicks3, Patrick Parfrey3. 1Department of Obstetrics and Gynecology; 2Medical Genetics Program; 3Clinical Epidemiology Unit; Memorial University of Newfoundland, St. Johns, NL, Canada.

11:30 - 13:30
P.01

LUNCH AND POSTER SESSION II


ACTIVATION OF AKT BY COOPERATION BETWEEN THE PI4KIII LIPID KINASE AND THE EEF1A2 ONCOGENE Anne A. Morrow, Jonathan M. Lee. Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada. NODAL ENDOSALPINGIOSIS IN OVARIAN SEROUS TUMORS OF LOW MALIGNANT POTENTIAL WITH LYMPH NODE INVOLVEMENT: A CASE FOR A PRECURSOR LESION Bojana Djordjevic1, Stacia Clement-Kruzel2, Neely Atkinson3, Anais Malpica1. 1Department of Pathology; 2Department of Pathology and Laboratory Medicine; 3Department of Biostatistics; The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. MICRORNA 376C ENHANCES OVARIAN CANCER CELL SURVIVAL BY TARGETING ACTIVIN RECEPTOR-LIKE KINASE 7: IMPLICATION IN CHEMORESISTANCE Gang Ye1, Guodong Fu1, Sufen Zhao1,4, Yin Bai1, Yanfang Ding5, Shiying Cui5, Yaou Zhang2, Burton B. Yang3, Chun Peng1. 1 Department of Biology, York University, Toronto, ON, Canada; 2 Life Science Division, Tsinghua University, Shenzhen Campus, China; 3Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; 4The Second Affiliated Hospital of Hebei Medical University,
www.ccocr2010.org 29

P.05

P.08

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

MONDAY, MAY 17
Shijiazhuang, China; 5Department of Histology and Embryology, Dalian Medical University, Dalian, China. P.10 ACTIVATED BMP SIGNALLING DIFFERENTIALLY MODULATES CELL ADHESION AND MOTILITY DURING OVARIAN CANCER SPHEROID FORMATION AND ATTACHMENT Teresa Peart1,5, Yudith Ramo-Valdes1, Monique Bertrand1,2,3, Akira Sugimoto1,2, Michel Prefontaine1,2, Gabriel DiMatta1,3,4, Trevor Shepherd1,2,3,5. 1Translational Ovarian Cancer Research Program, London Regional Cancer Program; 2Department of Obstetrics and Gynaecology, The University of Western Ontario; 3Department of Oncology, The University of Western Ontario; 4Department of Biochemistry, The University of Western Ontario; 5Department of Anatomy and Cell Biology, The University of Western Ontario; London, ON, Canada. INHIBITION OF P53 REPRESSES E-CADHERIN EXPRESSION BY INCREASING DNA METHYLTRANSFERASE 1 AND PROMOTER METHYLATION IN SEROUS BORDERLINE OVARIAN TUMOR CELLS Jung-Chien Cheng, Nelly Auersperg, Peter Leung. Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada. THE OVARIAN MICROENVIRONMENT OVERCOMES THE ANTI-TUMOUR EFFECT OF SPARC ON OVARIAN CANCER PROGRESSION James Greenaway1, Anne Koehler2, Chris McCulloch2, Jim Petrik3, Theodore Brown1, Maurice Ringuette4. 1Samuel Lunenfeld Research Institute, Toronto; 2Matrix Dynamics, Faculty of Dentistry, University of Toronto, Toronto; 3Department of Biomedical Sciences, University of Guelph, Guelph; 4Department of Cell and Systems Biology, University of Toronto, Toronto; ON, Canada.

P.13

P.16

30

Final Programme

5th Canadian Conference on Ovarian Cancer Research

MONDAY, MAY 17
P.18 THE ORIGIN OF OVARIAN CANCERS: A UNIFYING HYPOTHESIS Nelly Auersperg. Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada. VEPH1 IS A NOVEL REGULATOR OF TGF-b SIGNALING IN OVARIAN CANCER CELLS Premalatha Shathasivam1,2,3, Alexandra Kollara1,3, Jeff Wrana1,4, Theodore Brown1,2,3. 1Samuel Lunenfeld Research Institute, Mount Sinai Hospital; 2Department of Physiology, University of Toronto; 3Department of Obstetrics and Gynecology, University of Toronto; 4Department of Medical Genetics and Microbiology, University of Toronto; Toronto, ON, Canada. CYCLIN G2 EXERTS ANTI-TUMOR EFFECTS ON OVARIAN CANCER CELLS Stefanie Bernaudo, Guodong Fu, Dan Rosman, Chun Peng. Department of Biology, York University, Toronto, ON, Canada. EPITHELIAL OVARIAN CANCER ASCITES CONFER PROTECTION AGAINST DRUG-INDUCED CYTOTOXICITY Denis Lane, Isabelle Matte, Claudine Rancourt, Alain Pich. Dpartement de Micro-Infectiologie, FMSS, Universit de Sherbrooke, Sherbrooke, QC, Canada. AKT ACTIVATION DECREASES BID EXPRESSION AND INHIBITS ITS CLEAVAGE LEADING TO TRAIL RESISTANCE IN OVARIAN CANCER CELLS Nadzeya Goncharenko-Khaider, Denis Lane, Isabelle Matte, Claudine Rancourt, Alain Pich. Microbiologie et Infectiologie, Universit de Sherbrooke, Sherbrooke, QC, Canada.

P.20

P.22

P.25

P.27

www.ccocr2010.org

31

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

MONDAY, MAY 17
P.28 EPITHELIAL OVARIAN CANCER ASCITES FACTOR(S) ENGAGE avb5 INTEGRIN LEADING TO FOCAL ADHESION KINASE (FAK) AND AKT ACTIVATION AND PROTECTION FROM TRAIL-INDUCED CELL DEATH Denis Lane, Nadzeya Goncharenko-Khaider, Claudine Rancourt, Alain Pich. Microbiologie et Infectiologie, Universit de Sherbrooke, Sherbrooke, QC, Canada. KIF14 AS A NOVEL THERAPEUTIC TARGET FOR OVARIAN CANCER Brigitte Theriault1, Sanja Pajovic1, Brenda Gallie1,2,3,4. 1Division of Applied Molecular Oncology, Ontario Cancer Institute; 2 Department of Medical Biophysics, University of Toronto; 3 Department of Molecular and Medical Genetics, University of Toronto; 4Division of Visual Science, Toronto Western Research Institute; Toronto, ON, Canada. INTERACTION BETWEEN TRANSFORMING GROWTH FACTOR b AND EPIDERMAL GROWTH FACTOR IN THE EPITHELIAL-MESENCHYMAL TRANSITION OF EPITHELIAL OVARIAN CANCER CELLS YangXin Fu, Zhihua Xu. Department of Obstetrics and Gynecology, Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. HOXA4 REGULATES ALPHA3 INTEGRIN IN OVARIAN CANCER CELLS Christian Klausen, Nelly Auersperg, Peter C.K. Leung. Department of Obstetrics & Gynaecology, University of British Columbia, Vancouver, BC, Canada.

P.33

P.36

P.38

32

Final Programme

5th Canadian Conference on Ovarian Cancer Research

MONDAY, MAY 17
P.40 GPR30 IMMUNODETECTION IN HUMAN OVARIAN SURFACE EPITHELIUM Mara del Carmen Mndez1, Delia Prez-Montiel2, Silvia ReyesMaya1, Flavia Morales-Vsquez3, Georgina Rodrguez1, Mara Jos Gmora1, Vernica Daz-Hernndez1, Carmen Guadalupe Mondragn1, Enrique Pedernera1. 1Departamento de Embriologa, Facultad de Medicina, Universidad Nacional Autnoma de Mxico; 2 Departamento de Patologa, Instituto Nacional de Cancerologa; 3 Oncologa Mdica, Instituto Nacional de Cancerologa; Cd. de Mxico, D.F. Mxico. EVIDENCE OF THE PRESENCE OF A TUMOR SUPPRESSOR GENE IN 3P12-CEN REGION BY MICROCELL-MEDIATED CHROMOSOME TRANSFER IN A MODEL OF EPITHELIAL OVARIAN CANCER Karen Gambaro1, Manon de Ladurantaye2, Kim Leclerc Dsaulniers2, Jean-Sbastien Ripeau4,5, Suzanna Arcand4, Jose Lavoie3, Diane M. Provencher2,6, Anne-Marie Mes-Masson2,6, Mario Chevrette4,5, Patricia N. Tonin1,4,7. 1Department of Human Genetics, McGill University; 2Centre de recherche du Centre hospitalier de lUniversit de Montral / Institut du Cancer de Montral; 3Department of Pathology, McGill University; 4The Research Institute of McGill University Health Centre and Department of Medicine, McGill University; 5Department of Surgery, Urology Division, McGill University; 6Division de gyncologie oncologique, Universit de Montral; 7Department of Medicine, McGill University; Montral, QC, Canada.

P.42

www.ccocr2010.org

33

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

MONDAY, MAY 17
P.44 INHIBITION OF THE S100A6 PROTEIN OVER-EXPRESSED IN 3D SPHEROID MODELS OF EPITHELIAL OVARIAN CANCER (EOC) IMPACTS CELLULAR MIGRATION Magdalena Zietarska1, Liliane Meunier1, Julie Lafontaine1, Diane Provencher1,3, Patricia Tonin2,4, Anne-Marie Mes-Masson1,5. 1 Centre de Recherche du Centre Hospitalier de lUniversit de Montral (CHUM) / Institut du cancer de Montral; 2The Research Institute of the McGill University Health Centre; 3Dpartement dobsttrique-gyncologie, Universit de Montral; 4Departments of Human Genetics and Medicine, McGill University; 5 Dpartement de Mdecine, Universit de Montral; Montral, QC, Canada. THE ROLE OF HOXA7 AND PAX8 GENE EXPRESSION IN EPITHELIAL OVARIAN CANCER DIFFERENTIATION Elizabeth MG Pitre1,2, Ken Garson2, Barbara C Vanderhyden1,2. 1 Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa; 2Centre for Cancer Therapeutics, Ottawa Hospital Research Institute; Ottawa, ON, Canada. GELSOLIN MODULATES CISPLATIN SENSITIVITY: A DETERMINANT FOR CHEMOSENSITIVITY IN HUMAN CANCER Mohammad Reza Abedini1,2, Ann Ann Ding3, Ming Ju Cao1, DarBin Shieh3, Benjamin K. Tsang1. 1Departments of Obstetrics & Gynaecology and Cellular & Molecular Medicine, University of Ottawa; Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada; 2Department of Physiology and Pharmacology, Birjand University of Medical Sciences, Iran; 3 Institute of Oral Medicine, National Cheng Kung University, Tainan, Taiwan. GONADOTROPINS REGULATE THE EXPRESSION OF N- AND E-CADHERINS IN THE CHICKEN EMBRYO OVARY Jeannette Gnther, Maria del Carmen Mndez, Georgina Rodrguez, Carmen Mondragn, Enrique Pedernera. Departamento de Embriologa, Facultad de Medicina, Universidad Nacional Autnoma de Mxico, Mexico.

P.46

P.48

P.52

34

Final Programme

5th Canadian Conference on Ovarian Cancer Research

MONDAY, MAY 17
P.54 DIFFERENTIAL EFFECTS OF REPRODUCTIVE STEROID HORMONES ON OVARIAN CANCER PROGRESSION IN PRE- VS. POST-MENOPAUSAL OVARIES Kendra Hodgkinson1,2, Laura Laviolette1,2, Carolina PerezIratxeta3,4, Barbara Vanderhyden1,2. 1Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa; 2 Ottawa Hospital Research Institute Centre for Cancer Therapeutics; 3Regenerative Medicine, Ottawa Hospital Research Institute; 4Ontario Genomics Innovation Centre; Ottawa, ON, Canada. CHARACTERIZATION OF OVARIAN CANCER ASCITES ON CELL MIGRATION AND GENE EXPRESSION IN AN IN VITRO MODEL Liliane Meunier1, Marie-Line Puiffe1, Ccile Le Page1, Abdelali Filali-Mouhim1, Mario Chevrette2, Patricia N. Tonin2,3, Diane M. Provencher1,4,5, Anne-Marie Mes-Masson1,5. 1Centre de recherche du Centre hospitalier de lUniversit de Montral / Institut du Cancer de Montral; 2The Research Institute of the McGill University Health Centre; 3Department of Human Genetics, McGill University; 4Division of Gynecologic Oncology /Universit de Montral; 5Dpartement de Mdicine, Universit de Montral; Montral, QC, Canada. INVESTIGATION OF CHROMOSOME 17 TRANSCRIPTOME PATTERNS FROM VARIOUS EPITHELIAL CANCER MODELS Paulina Wojnarowicz1, Suzanna Arcand1, Diane Provencher3, Anne-Marie Mes-Masson3, Patricia N Tonin1,2,4. 1Department of Human Genetics, McGill University; 2The Research Institute of the McGill University Health Centre; 3Centre de recherche du centre Hospitalier de lUniversit de Montral/Institut de Cancer de Montral; 4Department of Medicine, McGill University; Montral, QC, Canada.

P.58

P.60

www.ccocr2010.org

35

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

MONDAY, MAY 17
P.61 ROLE OF BTF4 IN OVARIAN CANCER BIOLOGY Patrick Bondza1, Ccile Le Page1, Louis Cyr1, Diane Provencher1,3, Anne-Marie Mes-Masson1,2, Jean-Francois Cailhier1,2. 1Institut du Cancer de Montral, CR-CHUM, Universit de Montral; 2 Dpartement de Mdecine, Universit de Montral; 3Dpartement de gyncologie et obsttrique, Universit de Montral; Montral, QC, Canada. CHARACTERIZATION OF NINE NEW CELL LINES DERIVED FROM PRE- AND POST-CHEMOTHERAPY SAMPLES AND DETERMINATION OF THEIR DRUG RESISTANCE STATUS Isabelle Letourneau1, Lu-Lin Wang1, Louis Cyr1, Ccile Le Page1, Patricia Tonin3,4, Diane Provencher1,5, Anne-Marie Mes-Masson1,2. 1 Centre de recherche du Center hospitalier de lUniversit de Montral (CR-CHUM)/ Institut du cancer de Montral; 2 Dpartement de mdicine, Universit de Montral; 3Departments of Human Genetics and Medicine, McGill University; 4The Research Institute of the McGill University Health Centre; 5 Dpartement de gyncologie et obsttrique/Universit de Montral; Montral, QC, Canada. THE CHICK CHORIOALLANTOIC MEMBRANE (CAM) AS AN EX VIVO MODEL SYSTEM TO STUDY EPITHELIAL OVARIAN TUMOUR GROWTH AND METASTASIS Jason Reed1,2, Rohann Correa1,3, Yudith Ramos Valds1, Daniela M. Dinulescu7, Barbara C. Vanderhyden8, John D. Lewis5,6, Gabriel E. DiMattia1,3,4, Trevor G. Shepherd1,2,4,5. 1Translational Ovarian Cancer Research Program, London Regional Cancer Program, London, ON, Canada; 2Department of Anatomy and Cell Biology, The University of Western Ontario, London, ON, Canada; 3 Department of Biochemistry, The University of Western Ontario, London, ON, Canada; 4Department of Obstetrics and Gynaecology, The University of Western Ontario, London, ON, Canada; 5 Department of Oncology, The University of Western Ontario, London, ON, Canada; 6Department of Medical Biophysics, The University of Western Ontario, London, ON, Canada; 7Brigham and Womens Hospital, Cambridge, MA, USA; 8Ottawa Hospital Research Institute, Ottawa, ON, Canada.

P.62

P.63

36

Final Programme

5th Canadian Conference on Ovarian Cancer Research

MONDAY, MAY 17 13:30 - 16:30 SYMPOSIUM III: MODELS OF OVARIAN CANCER FOR MECHANISTIC AND THERAPEUTIC STUDIES
Co-chairs: Jonathan M. Lee, University of Ottawa, Ottawa, ON, Canada. Mark Nachtigal, Dalhousie University, Halifax, NS, Canada. Ovarian cancer is a challenging disease to understand, partly due to the difficulty in generating models of this disease. In order to develop novel and efficacious treatment strategies, well-designed models of ovarian cancer are imperative. Careful modeling of ovarian cancer will allow us to develop translational studies that can take our research from the bench to the bedside. In this symposium, Drs. Connolly, Petrik, and Kerbel will present their insights into the use of animal models of ovarian cancer and how information from these models can translate to effective therapies.

13:30 - 14:00

FOCAL ADHESION PROTEIN SIGNALING IN OVARIAN CARCINOMA


Denise C. Connolly, Fox Chase Cancer Center, Philadelphia, PA, USA.

14:00 - 14:15

E-CADHERIN INHIBITS TUMOR CELL GROWTH BY SUPPRESSING PI3K/AKT SIGNALING VIA BETA-CATENIN-MEDIATED PTEN EXPRESSION
Man-Tat Lau, Christian Klausen, Peter C.K. Leung. Department of Obstetrics and Gynecology, Child and Family Research Institute, University of British Columbia, Vancouver, BC, Canada.

14:15 - 14:30

NON-ADHERENT CULTURE OF PRIMARY EPITHELIAL OVARIAN CANCER CELLS INDUCES AUTOPHAGY, SUPPRESSES PROLIFERATION, AND REDUCES AKT ACTIVITY
Rohann Correa1,2, Yudith Ramos-Valdes1, Monique Bertrand1,3,4, Michel Prefontaine1,3, Akira Sugimoto1,3,4, Trevor Shepherd1,3,4,5, Gabriel DiMattia1,2,4. 1Translational Ovarian Cancer Research
www.ccocr2010.org 37

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

MONDAY, MAY 17
Program, London Regional Cancer Centre; 2Department of Biochemistry, Schulich School of Medicine and Dentistry, University of Western Ontario; 3Department of Obstetrics & Gynaecology, Schulich School of Medicine and Dentistry, University of Western Ontario; 4Department of Oncology, Schulich School of Medicine and Dentistry, University of Western Ontario; 5 Department of Anatomy & Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario; London, ON, Canada.

14:30 - 15:00

A TRANSLATIONAL RESEARCH STRATEGY FOR DESIGNING MORE EFFECTIVE TREATMENTS FOR ADVANCED OVARIAN CANCER
Robert S. Kerbel, Sunnybrook Health Sciences Centre, Toronto, Canada.

15:00 - 15:30 15:30 - 16:00

COFFEE BREAK THE IMPORTANCE OF THE OVARIAN STROMA IN THE ONSET AND PROGRESSION OF EPITHELIAL OVARIAN CANCER
Jim Petrik, University of Guelph, Guelph, ON, Canada.

38

Final Programme

5th Canadian Conference on Ovarian Cancer Research

MONDAY, MAY 17 16:00 - 16:15 MOUSE MODELS FOR TUBAL CARCINOGENESIS: OVIDUCTAL GLYCOPROTEIN 1 (OGP1)-PROMOTER DRIVEN, TEMPORALLY CONTROLLED CRE EXPRESSION IN MOUSE FALLOPIAN EPITHELIUM
Takayo Ota1, Wei Zhou2, Viji Shridhar1, Jan van Deursen2, Jeremy Chien1. 1Department of Experimental Pathology; 2Department of Pediatric and Adolescent Medicine; Mayo Clinic College of Medicine, Rochester, MN, USA.

16:15 - 16:30

POSITIONAL CLONING OF THE GCT1 GRANULOSA CELL TUMOUR SUSCEPTIBILITY LOCUS IN SWR/BM INBRED MICE
K.N. Smith1, S.J. Halfyard1, K.L. Shultz2, W.G. Beamer2, A. HeraviMoussavi3, D. Huntsman3, A.M. Dorward1. 1Division of BioMedical Sciences, Faculty of Medicine, Memorial University, St. Johns, NL, Canada; 2The Jackson Laboratory, Bar Harbor, ME, USA; 3Centre for Translational and Applied Genomics, British Columbia Cancer Agency, Vancouver, BC, Canada.

16:30 - 18:00

WORKSHOP I
During this workshop we will have discussion on the following four topics: 1) Biobanking needs related to OV21 (An NCIC phase II/III study of intraperitoneal (IP) plus intravenous (IV) chemotherapy versus IV carboplatin plus paclitaxel in patients with epithelial ovarian cancer optimally debulked at surgery following neoadjuvant intravenous chemotherapy) Study Summary Website: www.gcig.igcs.org/files/ov21_summary.pdf Leads: Helen Mackay and Diane Provencher 2) The Terry Fox Research Institute (TFRI) Coeur Program Program Website: www.tfri.ca/programs/institute_2008-03T.asp Leads: David Huntsman and Anne-Marie Mes-Masson 3) The rich clinical data available, access to this data and optimization of data quality Leads: Barry Rosen 4) Ethics, institutional access policies and material transfer agreements. Leads: Jeremy Squire and Anne-Marie Mes-Masson

19:00

SOCIAL EVENT IN THE DISTILLERY DISTRICT


Please refer to page 11 for details.
www.ccocr2010.org 39

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

TUESDAY, MAY 18 07:30 - 08:30 08:30 - 11:30 BREAKFAST SYMPOSIUM IV: TARGETED THERAPIES AND CURRENT AND EMERGENT CLINICAL TRIALS
Co-Chairs: Brad Nelson, BC Cancer Agency, Victoria, BC, Canada. Amit Oza, Princess Margaret Hospital, Toronto, ON, Canada. Chaired by Drs. Amit Oza and Brad Nelson, both prominent Canadian ovarian cancer investigators who will bring a depth of expertise and insight into the issues, this symposium will explore many aspects of bringing molecular biology to clinical therapeutics, the bench to the bedside. We are honoured to welcome an auspicious faculty including Dr. Elise Kohn of the NCI/NIH, Bethesda whose work in markers for early detection, identification of molecular therapeutic targets and other translational themes has heavily influenced ovarian cancer research in North America and beyond. Dr. Janet Dancey has recently returned from NIH to her native Canada to take on joint roles in translational science at NCIC and OICR. In these roles, she will facilitate the translation of discoveries from laboratory to clinic by providing infrastructure and resources to support trials evaluating markers for early diagnosis, prognosis, and predication of benefit to help develop better treatments for cancer patients.

08:30 - 09:00

NEW DIRECTION FOR THERAPY OF OVARIAN CANCER


Elise C. Kohn, National Cancer Institute, Bethesda, MD, USA.

09:00 - 09:15

THE ROLE OF AURORA A KINASE IN OVARIAN CANCER GROWTH AND DISSEMINATION


Thuy-Vy Do1, Laura Bickel1, Xiang Hua1, Russell Schilder2, Denise Connolly1. 1Womens Cancer Program; 2Department of Medical Oncology; Fox Chase Cancer Center, Philadelphia, PA, USA.

40

Final Programme

5th Canadian Conference on Ovarian Cancer Research

TUESDAY, MAY 18 09:15 - 9:30 HYPERGLYCEMIA ACCELERATES THE PROGRESSION OF EPITHELIAL OVARIAN CANCER AND ANTI-HYPERGLYCEMIC DRUGS OFFER NOVEL TREATMENT OPPORTUNITIES
Lisa Kellenberger1, Alison Holloway2, Hertzel Gerstein3, Jim Petrik1. 1Biomedical Sciences, University of Guelph, Guelph; 2 Department of Obstetrics and Gynaecology, McMaster University, Hamilton; 3Division of Endocrinology and Metabolism, McMaster University, Hamilton; ON, Canada.

09:30 - 10:00

TARGETED THERAPY IN CLINICAL TRIALS: CURRENT STATUS AND FUTURE DIRECTIONS


Janet Dancey, National Cancer Institute of Canada, Kingston, ON, Canada.

10:00 - 10:30 10:30 - 10:45

COFFEE BREAK TREATMENT WITH THE THROMBOSPONDIN-1 MIMETIC PEPTIDE ABT-898 INDUCES TUMOUR REGRESSION AND PROLONGS SURVIVAL IN A MOUSE MODEL OF EPITHELIAL OVARIAN CANCER
Nicole Campbell1, Jack Henkin2, Jim Petrik1. 1University of Guelph, Guelph, ON, Canada; 2Abbott Laboratories, Abbott Park, IL, USA.

10:45 - 11:00

AB-3D3, A THERAPEUTIC IGG1 MONOCLONAL ANTIBODY THAT SPECIFICALLY TARGETS OVARIAN CANCER
Gilles Tremblay1, Aida Kalbakji1, Valrie Bdard1, Annie Fortin1, Martine Pag1, Marc Sasseville1, Anne-Marie Mes-Masson2, Mario Filion1. 1Alethia Biotherapeutics; 2Dept. of Oncology, Centre Hospitalier de lUniversit de Montral; Montral, QC, Canada.

www.ccocr2010.org

41

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

TUESDAY, MAY 18 11:00 - 11:15 TUBAL INTRAEPITHELIAL CARCINOGENESIS SCREENING (TICS) USING OPTICAL TECHNOLOGIES
Jessica McAlpine1, Pierre Lane2, Sylvia Lam2, Steve Kalloger3, Margaret Luk3, David Huntsman4, C. Blake Gilks3, Calum MacAulay2, Dianne Miller1. 1Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, University of British Columbia; 2Department of Integrative Oncology, BC Cancer Agency; 3Department of Pathology and Laboratory Medicine, University of British Columbia; 4Centre for the Translational & Applied Genomics, BC Cancer Agency; Vancouver, BC, Canada.

11:15 - 13:30
P.03

LUNCH AND POSTER SESSION III


ACTIVATED AKT SIGNALLING IS REQUIRED FOR MYXOMA VIRUS-MEDIATED ONCOLYSIS OF ASCITES-DERIVED HUMAN EPITHELIAL OVARIAN CANCER CELLS AND SPHEROIDS Monica Komar1,2, Rohann Correa1,3, Monique Bertrand1,4,5, Michel Prefontaine1,4, Akira Sugimoto1,4, Grant McFadden7, Gabriel E. DiMattia1,3,5, Trevor G. Shepherd1,4,5,6. 1Translational Ovarian Cancer Research Program, London Regional Cancer Program, London, ON, Canada; 2Department of Biology, The University of Western Ontario, London, ON, Canada; 3Department of Biochemistry, The University of Western Ontario, London, ON, Canada; 4Department of Obstetrics & Gynaecology, The University of Western Ontario, London, ON, Canada; 5Department of Oncology, The University of Western Ontario, London, ON, Canada; 6Department of Anatomy & Cell Biology, The University of Western Ontario, London, ON, Canada; 7Department of Molecular Genetics & Microbiology, University of Florida, Gainesville, FL, USA.

42

Final Programme

5th Canadian Conference on Ovarian Cancer Research

TUESDAY, MAY 18
P.07 THERAPEUTIC ADVANTAGES OF CONTINUOUS CHEMOTHERAPY IN THE TREATMENT OF ADVANCED EPITHELIAL OVARIAN CANCER Raquel De Souza1, Payam Zahedi1, Eduardo Moriyama2, Christine Allen1, Brian Wilson2, Micheline Piquette-Miller1. 1Department of Pharmaceutical Sciences; 2Department of Medical Biophysics; University of Toronto, Toronto, ON, Canada. CYTOKINE-MEDIATED REPROGRAMMING OF POLYFUNCTIONAL CD8+ T-CELL RESPONSES IN THE OVARIAN CANCER MICROENVIRONMENT Eric Tran1,2, Julie S. Nielsen2, Darin A. Wick2, Alvin Ng2, Nancy J. Nessliner2, Elissa McMurtrie3, John R. Webb1,2, Brad H. Nelson1,2,4. 1Department of Microbiology and Biochemistry, University of Victoria, Victoria; 2Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria; 3BC Cancer Agency, Victoria; 4Department of Biology, University of Victoria, Victoria; 5Department of Medical Genetics, University of British Columbia, Vancouver; BC, Canada. STRONG CYTOTOXIC EFFECT OF THE BRADYKININ ANTAGONIST BKM570 IN OVARIAN CANCER CELLS: ANALYSIS OF THE MOLECULAR MECHANISMS OF ITS ANTI-PROLIFERATIVE ACTION Stephanie Jutras1, Magdalena Bachvarova5, Jean-Loup Bascands3, Anne-Marie Mes-Masson2, John Stewart4, Dimcho Bachvarov1. 1 Laval University; 2Montral University; 3INSERM-Toulouse, France; 4University of Colorado, USA; 5CHUQ-Centre de recherche-HDQ, Qubec, QC, Canada. DIETARY INTERVENTION WITH FLAXSEED/OMEGA-3 FATTY ACIDS DECREASES INFLAMMATION AND REDUCES SEVERITY OF OVARIAN CANCER IN THE LAYING HEN GALLUS DOMESTICUS Dale Buck Hales1, Kristine Ansenberger2, Yan Zhuge4, Janice Bahr3. 1Department of Physiology, Southern Illinois University School of Medicine, Carbondale; 2Department of Physiology, University of Illinois College of Medicine, Chicago; 3Department of
www.ccocr2010.org 43

P.11

P.15

P.19

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

TUESDAY, MAY 18
Animal Sciences, University of Illinois Urbana Champaign, Urbana; 4Pharmacology Department, Rush University Medical Center, Chicago; IL, USA. P.23 AN ESSENTIAL ROLE FOR RAN GTPASE IN EPITHELIAL OVARIAN CANCER CELL SURVIVAL Vronique Barrs1, Vronique Ouellet1, Julie Lafontaine1, Patricia N. Tonin2, Diane M. Provencher1, Anne-Marie Mes-Masson1. 1 Institut du Cancer de Montral/CR-CHUM; 2The Research Institute of McGill University Health Centre (RI-MUHC); Montral, QC, Canada. TUMOR GROWTH INHIBITION BY PARP INHIBITOR OLAPARIB IN BRCA2 GERMLINE-MUTATED PATIENT DERIVED OVARIAN CANCER TISSUE XENOGRAFTS Ursula Kortmann1,2, Jessica McAlpine3, Hui Xue2, Alan Lau4, Aaron Cranston4, Mark J. OConnor4, David G. Huntsman1,5, Yuzhuo Wang2,6, C. Blake Gilks5. 1Department of Pathology and Laboratory Medicine, BC Cancer Agency and University of British Columbia, Vancouver, BC, Canada; 2Living Tumor Laboratory, BC Cancer Agency, Vancouver, BC, Canada; 3Department of Pathology, Vancouver General Hospital, Vancouver, BC, Canada; 4 KuDOS Pharmaceuticals Ltd., Cambridge, UK; 5Department of Pathology, Genetic Pathology Evaluation Centre, Vancouver General Hospital, Centre for Translation and Applied Genomics, BC Cancer Agency and University of British Columbia, Vancouver, BC, Canada; 6The Prostate Centre at Vancouver General Hospital and Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. NOVEL EGFR-DNA COMBI-MOLECULES FOR THE TREATMENT OF ADVANCED OVARIAN CANCER Margarita Todorova, Ying Hoang, Zakaria Rachid, Bertrand Jean-Claude. Department of Oncology, Faculty of Medicine, McGill University, Montral, QC, Canada.

P.30

P.31

44

Final Programme

5th Canadian Conference on Ovarian Cancer Research

TUESDAY, MAY 18
P.35 THERAPEUTIC TESTING OF A NOVEL PKC INHIBITOR GAP-107B8 ON OVARIAN CANCER CELLS Fu Jian Yan1 3, Isabella Steffenson4, Kenneth Garson1 3, Barbara C Vanderhyden1 2 3. 1Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa; 2Department of Obstetrics and Gynecology, Faculty of Medicine, University of Ottawa; 3Centre for Cancer Therapeutics, Ottawa Hospital Research Institute; 4PharmaGap Inc.; Ottawa, ON, Canada. THE ROLE OF THE ELECTRONIC HEALTH RECORD IN SUPPORT OF GENOMIC RESEARCH Vincent Normandeau-Babin1, Hanad Nwilati2, Sherif Abou-Elela2, Andrew Grant1. 1Collaborative Research for Effective Diagnostics (CRED); 2Laboratoire de Gnomique Fonctionnelle de lUniversit de Sherbrooke (LGFUS); Universit de Sherbrooke, Sherbrooke, QC, Canada. FEASIBILITY AND ACCURACY OF IMAGE-GUIDED TISSUE BIOPSIES: PREPARING FOR A SHIFTING PARADIGM IN THE MANAGEMENT OF OVARIAN CANCER Jessica McAlpine1, O.M. Al-Agha2, A. Oza3, G. Turashvili4, H. Hirte5, S. Kalloger2, D. Jepson6, M. Martin7, S. Aparicio4, K. Gelmon6. 1Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, University of British Columbia, Vancouver, BC; 2Department of Pathology and the Centre for Translational & Applied Genomics, BC Cancer Agency, Vancouver, BC; 3 Department of Hematology-Oncology, Princess Margaret Hospital, Toronto, ON; 4Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC; 5Department of Oncology, Division of Medical Oncology, Juravinski Cancer Centre, Hamilton, ON; 6Department of Medical Oncology, BC Cancer Centre, Vancouver, BC; 7Department of Diagnostic Imaging, BC Cancer Agency, Vancouver, BC; Canada.

P.39

P.43

www.ccocr2010.org

45

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

TUESDAY, MAY 18
P.50 DEVELOPMENT OF A HUMAN IN VITRO MODEL OF OVARIAN CARCINOGENESIS Sophia George1, Anca Milea2, Sanjeev Shaw3, Hal Berman4, Mona Gauthier2, Patricia Shaw2. 1University of Toronto; 2University Health Network; 3Department of Laboratory Medicine; 4Campbell Family Institute for Breast Cancer Research; Toronto, ON, Canada. DEVELOPMENT AND VALIDATION OF AN IMMUNOHISTOCHEMICAL PANEL FOR THE SUBTYPING OF OVARIAN CARCINOMA: IMPLICATIONS FOR THE POST-NCIC-CTG OV 13 WORLD Steve E. Kalloger1,2,3, Martin Kbel4, Samuel Leung3, Erika Mehl3, Dongxia Gao3, Krista Marcon3, Christine Chow3, David G. Huntsman1,3, C. Blake Gilks2,3. 1Centre for Translational and Applied Genomics, British Columbia Cancer Agency, Vancouver, BC; 2Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, BC; 3Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC; 4Department of Pathology and Laboratory Medicine, University of Calgary, Calgary Laboratory Services, Calgary, AB; Canada. COMPARING BIOMARKER EXPRESSION FROM OVARIAN AND OMENTAL SITES IN PELVIC HIGH-GRADE SEROUS CARCINOMAS Martin Kbel1, Dmitry Turbin2, Steve E Kalloger2, Dongxia Gao2, David G Huntsman2, C Blake Gilks2. 1Department of Pathology and Laboratory Medicine, University of Calgary, AB, Canada; 2Genetic Pathology Evaluation Centre, Vancouver General Hospital and the British Columbia Cancer Agency, Vancouver, BC, Canada.

P.51

P.56

46

Final Programme

5th Canadian Conference on Ovarian Cancer Research

TUESDAY, MAY 18
P.59 INACTIVATED P53 OR INCREASED ESTROGEN LEVELS OCCURRING CONCOMITANTLY WITH BRCA1 INACTIVATION CONTRIBUTE TO BRCA1-ASSOCIATED OVARIAN TUMOURIGENESIS Sara Rafferty, Katherine Clark-Knowles, Jin-Yi Jiang, Laura Laviolette, Barbara Vanderhyden. Department of Cellular and Molecular Medicine, University of Ottawa, and Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada. IMPACT OF C282Y AND H63D MUTATIONS IN THE HEMOCHROMATOSIS GENE (HFE) ON EPITHELIAL OVARIAN CANCER RISK AND SURVIVAL Philippe Gannon, Sanae Medelci, Layoun Antonio, Ccile Le Page, Marie Beaulieu, Diane Provencher, Anne-Marie Mes-Masson, Manula Santos. Centre de recherche du Centre hospitalier de lUniversit de Montral (CRCHUM) and Institut du Cancer de Montral; Division of Gynecologic Oncology, Universit de Montral; Department of Medicine, Universit de Montral; Montral, QC, Canada. PROGNOSTIC FACTORS FOR EPITHELIAL OVARIAN CANCER: A PILOT STUDY TO EXAMINE ANDROGEN HORMONE HOMEOSTASIS Joel Moody1,2, Barry Rosen3, Steven Narod4, Isabel Fan1, John McLaughlin1,2. 1Prosserman Centre for Health Research, Samuel Lunenfeld Research Institute, Mt. Sinai Hospital; 2Dalla Lana School of Public Health, University of Toronto; 3Familial Ovarian Cancer Clinic, Princess Margaret Hospital; 4Centre for Research in Womens Health, Womens College Hospital; Toronto ON, Canada.

P.65

P.67

www.ccocr2010.org

47

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

TUESDAY, MAY 18 13:30 - 15:30 WORKSHOP II


Workshop II will focus on discussion of the imminent impact of targeted therapeutics, molecular approaches to treatment and individualized cancer therapies on the ways in which we will evaluate these new treatments, including clinical trials. Participants will focus on the new opportunities and challenges anticipated in transition from our current clinical trials structure to this new paradigm, specifically within the Canadian context. Dr. Janet Dancey, NCIC Director of Translational Research and OICR Program Leader, High Impact Clinical Trials will chair; discussants will be Dr. Jeremy Squire, NCIC Director of Translational Laboratory Research and Dr. Amit Oza, Co-Chair of the NCIC Gyn Site Committee and a co-director of the Robert and Maggie Bras Drug Development Program at Princess Margaret Hospital. With their depth of experience and wealth of expertise in new drugs and targeted therapies and their evaluation in vivo, exchange among this faculty and participants will explore the implications of our emerging molecular understanding of disease and of therapies targeted specifically at these demonstrated mechanisms of disease. Implications for investigators and academic clinicians/trialists and for trial methodology in human subjects will be discussed.

15:30 - 17:00

BRIEF REPORTS OF WORKSHOPS, SUMMARY, AWARDS AND FAREWELL

48

Final Programme

5th Canadian Conference on Ovarian Cancer Research

Index of Presenters
Abedini, Mohammad Reza Al-Agha, Osama M. Arcand, Suzanna L. Ashworth, Alan Auersperg, Nelly Bachvarov, Dimcho Barrs, Vronique Bayani, Jane Bernaudo, Stefanie Birch, Ashley Brosseau, Jean-Philippe Brown, Patrick O. Caceres, Katia Y. Campbell, Nicole Carey, Mark S. Carmona, Euridice Cheng, Jung-Chien Connolly, Denise C. Correa, Rohann Crum, Christopher Cui, Shiying Dancey, Janet Dawson, Lesa De Souza, Raquel Daz-Hernndez, Vernica Dick, John Djordjevic, Bojana Do, Thuy-Vy Durbin, Joshua Elschenbroich, Sarah Fu, YangXin Gambaro, Karen George, Sophia Goncharenko-Khaider, Nadzeya Greenaway, James Gnther, Jeannette Hales, Dale Buck Monday11:30P.48 Sunday17:00P.02 Sunday17:00P.47 Sunday16:30 Monday11:30P.18 Tuesday11:15P.15 Tuesday11:15P.23 Sunday17:00P.57 Monday11:30P.22 Sunday17:00P.55 Sunday17:00P.24 Sunday14:00 Sunday17:00P.09 Tuesday10:30 Sunday15:00 Sunday16:15 Monday11:30P.13 Monday13:30 Monday14:15 Monday09:30 Sunday17:00P.32 Tuesday09:30 Monday11:15 Tuesday11:15P.07 Monday11:30P.40 Monday08:30 Monday11:30P.05 Tuesday09:00 Sunday17:00P.14 Sunday17:00P.66 Monday11:30P.36 Monday11:30P.42 Tuesday11:15P.50 Monday11:30P.27, P.28 Monday11:30P.16 Monday11:30P.52 Tuesday11:15P.19
www.ccocr2010.org 49

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

Haslehurst, Alexandria Haw, Robin Hodgkinson, Kendra Huntsman, David Jean-Claude, Bertrand Kalatskaya, Irina Kalloger, Steve E. Kellenberger, Lisa Kerbel, Robert S. Kislinger, Thomas Klausen, Christian Klinck, Roscoe Kbel, Martin Kohn, Elise Kortmann, Ursula Koti, Madhuri Kulasingam, Vathany Kuzmanov, Uros Lanner, Carita Lau, Man-Tat Le Page, Ccile Lee, Jonathan M. Matte, Isabelle McAlpine, Jessica Medrano, Mauricio A. Mndez, Mara del Carmen Meunier, Liliane Milea, Anca Moody, Joel Narod, Steven Nelson, Brad H. Nwilati, Hanad Ota, Takayo Peart, Teresa Petrik, Jim Pitre, Elizabeth MG Prinos, Panagiotis
50 Final Programme

Sunday17:00P.17 Sunday17:00P.37 Monday11:30P.54 Sunday14:30 Tuesday11:15P.31 Sunday17:00P.41 Tuesday11:15P.51 Tuesday09:15 Monday14:30 Sunday15:45 Monday11:30P.38 Sunday17:00P.21 Tuesday11:15P.56 Tuesday08:30 Sunday17:00P.12, Tuesday11:15P.30 Sunday17:00P.26 Sunday17:00P.64 Sunday17:00P.34 Sunday-17:00-P.69 Monday14:00 Monday11:30P.61, P.62 Tuesday11:15P.65 Monday11:30P.01 Monday11:30P.25 Tuesday11:15P.43, Tuesday11:00 Sunday17:00P.45 Sunday17:00P.29 Monday11:30P.58 Sunday17:00P.04 Tuesday11:15P.67 Monday10:45 Tuesday11:15P.11 Tuesday11:15P.39 Monday16:00 Monday11:30P.10 Monday15:30 Monday11:30P.46 Sunday17:00P.68

5th Canadian Conference on Ovarian Cancer Research

Quinn, Michael Rafferty, Sara Reed, Jason Shathasivam, Premalatha Shepherd, Trevor G. Smith, Kerri Stewart, Jocelyn Theriault, Brigitte Tone, Alicia Tremblay, Gilles Trudel, Dominique Turchet, Lisa Wells, Heidi Wojnarowicz, Paulina Yan, Fu Jian Ye, Gang Zietarska, Magdalena

Sunday17:00P.53 Tuesday11:15P.59 Monday11:30P.63 Monday11:30P.20 Tuesday11:15P.03 Monday16:15 Monday09:15 Monday11:30P.33 Monday10:30 Tuesday10:45 Sunday17:00P.06 Monday09:00 Sunday17:00P.49 Monday11:30P.60 Tuesday11:15P.35 Monday11:30P.08 Monday11:30P.44

www.ccocr2010.org

51

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

Delegate Directory
Abedini, Dr. Mohammad Reza OHRI Ottawa ON Tel.: 613-798 5555 X 18082 mabedini@ohri.ca Al-Agha, Dr. Osama British Columbia Cancer Agency and Genetic Pathology Evaluation Centre, Vancouver General Hospital Vancouver, BC Tel.: 604-727-6647 osama.alagha@vch.ca Ali, Dr. Ahmed Ottawa Hospital Research Institute Ottawa, ON Tel.: 613-798-5555 X 13713 aali@ohri.ca Arcand, Ms. Suzanna Research Institute of the MUHC Montral, QC Tel.: 514-934-1934 X 44201 suzanna.arcand@mail.mcgill.ca Ashworth, Prof. Alan The Institute of Cancer Research London Tel.: +44-20-7153-5333 alan.ashworth@icr.ac.uk Auersperg, Dr. Nelly University of British Columbia Vancouver, BC Tel.: 604-736-4758 auersper@interchange.ubc.ca Bachvarov, Prof. Dimcho Laval University Qubec, QC Tel.: 418-525-4444 X 15590 dimtcho.batchvarov@crhdq.ulaval.ca
52 Final Programme

Barrs, Mrs. Vronique Institut du cancer de Montral Montral, QC Tel.: 514-890-8000 X 24647 veronique.barres@gmail.com Batchvarova, Mrs. Magdalena CHUQ Qubec, QC Tel.: 418-525-4444 X 24651 magdalenab3@hotmail.com Bayani, Ms. Jane University of Toronto Toronto, ON Tel.: 416-586-4800 X 8813 jane.bayani@utoronto.ca Beauchamp, Dr. Marie-Claude Jewish General Hospital Montral, QC Tel.: 514-340-8222 X 2979
marie-claude.beauchamp2@mail.mcgill.ca

Bernardini, Dr. Marcus Princess Margaret Hospital Toronto, ON Tel.: 416-946-4501 X 2668 marcus.bernardini@uhn.on.ca Bernaudo, Ms. Stefanie York University Woodbridge, ON Tel.: 416-529-1098 stefaniebernaudo@gmail.com Birch, Ms. Ashley McGill University Montral, QC Tel.: 514-750-5021 ashley.birch@mail.mcgill.ca Brosseau, Mr. Jean-Philippe Universit de Sherbrooke Sherbrooke, QC Tel.: 819-820-6868
jean-philippe.brosseau@USherbrooke.ca

Brown, Dr. Patrick O. Stanford University School of Medicine Stanford, CA Tel.: 650-723-0005 pbrown@stanford.edu Brown, Dr. Theodore Toronto Ovarian Cancer Research Network Toronto, ON Tel.: 416-946-4658 brown@mshri.on.ca Caceres, G. Mrs. Katia Y. Institut du cancer de Montral Montral, QC Tel.: 514-890-8000 X 24647 ky.caceres@gmail.com Campbell, Mrs. Nicole University of Guelph Guelph, ON Tel.: 519-830-5851 nsolinge@uoguelph.ca Carmona, Dr. Euridice Montral, QC Tel.: 514-252-3400 X 3341 ecarmona.hmr@ssss.gouv.qc.ca Chow, Dr. Jennifer Roche Canada (Hoffmann-La Roche Ltd.) Mississauga, ON Tel.: 905-542-5583 Jennifer.chow@roche.com Clarke, Dr. Blaise UHN/TGH Toronto, ON Tel.: 416-340-3396 blaise.clarke@uhn.on.ca Connolly, Dr. Denise C. Fox Chase Cancer Center Philadelphia, PA, USA Tel.: 215-728-1004 Denise.Connolly@fccc.edu

5th Canadian Conference on Ovarian Cancer Research

Correa, Mr. Rohann University of Western Ontario London, ON Tel.: 519-685-8600 X 53626 rcorrea4@uwo.ca Crosley, Mr. Powel Granulosa Cell Tumour Foundation St. Heliers, Auckland, New Zealand pcrosley@gctf.org.nz Crum, Dr. Christopher Brigham And Womens Hospital Boston, MA, USA Tel.: 617-732-5481 cpcrum@bics.bwh.harvard.edu Cui, Dr. Shiying Dalian Medical University Dalian, Liaoning, P.R. China Tel.: +86-411-86110314 scui2003@yahoo.ca Dancey, Dr. Janet Ontario Institute for Cancer Research Toronto, ON Tel.: 416-673-6532 janet.dancey@oicr.on.ca De Ita-Ley, Dr. Marlon UNAM Mxico, Mexico Tel.: 525556232264 morgan_lee77@hotmail.com Diaz-Hernandez, Dr. Veronica UNAM Mxico, Mexico Tel.: 525556232264 roveazdih@yahoo.com.mx Dick, Dr. John MaRS Centre Toronto, ON Tel.: 416-581-7466 jdick@uhnres.utoronto.ca

DiMattia, Dr. Gabriel London Regional Cancer Centre London, ON Tel.: 519-685-8600 X 53625 dimattia@uwo.ca Djordjevic, Dr. Bojana M.D. Anderson Cancer Center Houston, TX Tel.: 281-962-0585 bojana.djordjevic@utoronto.ca Do, Dr. Thuy-Vy Fox Chase Cancer Center Philadelphia, PA Tel.: 215-728-3679 Thuy-Vy.Do@fccc.edu Dor, Dr. Jules Memorial University of Newfoundland St. Johns, NL Tel.: 709-777-8573 jdore@mun.ca Durbin, Mr. Joshua University of Toronto Toronto, ON Tel.: 416-294-4122 j.durbin@utoronto.ca Elschenbroich, Ms. Sarah University Health Network Toronto, ON Tel.: 416-581-7644 selschen@uhnres.utoronto.ca Filion, Dr. Mario Alethia BioTherapeutics Montral, QC Tel.: 514-858-7666 X 207 mariof@alethiabio.com Finch, Ms. Amy Womens College Research Institute Toronto, ON Tel.: 416-351-3800 X 2751 amy.finch@wchospital.ca

Fletcher, Dr. Graham Entremed, Inc. Toronto, ON Tel.: 416-581-7596 grahamf@entremed.com Fu, Dr. Yang Xin University of Alberta Edmonton, AB Tel.: 780-492-2727 yangxin@ualberta.ca Gambaro, Dr. Karen McGill University Montral, QC Tel.: 514-934-1934 X 44201 karen.gambaro@mail.mcgill.ca Garson, Dr. Kenneth Ottawa Hospital Research Institute Ottawa, ON Tel.: 613-737-7700 kgarson@ohri.ca Goncharenko, Mrs. Nadzeya Universit de Sherbrooke Sherbrooke, QC Tel.: 819-575-9852 nadgoncharenko@yahoo.ca Greenaway, Dr. James Mount Sinai Hospital Toronto, ON Tel.: 416-586-4800 X 5601 james.greenaway@utoronto.ca Gnther, Dr. Jeannette Universidad Nacional Autunoma de Mxico Mexico City, Mexico Tel.: +52-55-562332264 quetzaljea@hotmail.com Hales, Prof. Dale Buck Southern Illinois University School of Medicine Carbondale, IL, USA Tel.: 618-453-1544 dhales@siumed.edu

www.ccocr2010.org

53

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

Hasan, Dr. Raghad Mississauga, ON Tel.: 905-232-9452 ayagafarme@yahoo.ca Haw, Dr. Robin OICR Toronto, ON Tel.: 647-260-7985 robin.haw@oicr.on.ca Heron, Dr. Frank Roche Canada (Hoffmann-La Roche Ltd.) Mississauga, ON Tel.: 905-542-5583 Frank.heron@roche.com Hodgkinson, Ms. Kendra University of Ottawa Ottawa, ON Tel.: 613-230-5507 khodg078@uottawa.ca Huntsman, Dr. David University of British Columbia Vancouver, BC Tel.: 604-877-6000 X 2148 dhuntsma@bccancer.bc.ca Jean-Claude, Dr. Bertrand McGill University, Cancer Drug Research Laboratory Montral, QC Tel.: 514-934-1934 X 35841 jacques.jeanclaude@mcgill.ca Kalatskaya, Dr. Irina OICR Toronto, ON Tel.: 647-260-7052 irina.kalatskaya@oicr.on.ca Kalloger, Mr. Steve Vancouver, BC Tel.: 604-889-0997 skalloger@me.com
54 Final Programme

Keita, Mr. Mamadou Laval University Qubec, QC Tel.: 418-525-4444 X 24651 mamadou.keita.1@ulaval.ca Kendall-Dupont, Mrs. Jennifer CHUM Montral, QC Tel.: 514-890-8000 X 25491 jen.kendalldupont@gmail.com Kerbel, Dr. Robert S. University of Toronto, Sunnybrook Health Sc. Centre Toronto, ON Tel.: 416-480-5711 robert.kerbel@sri.utoronto.ca Kerr, Ms. Amanda University of Guelph Guelph, ON Tel.: 519-820-9776 akerr01@uoguelph.ca Kislinger, Dr. Thomas University of Toronto Toronto, ON Tel.: 416-581-7627 thomas.kislinger@utoronto.ca Klausen, Dr. Christian University of British Columbia Vancouver, BC Tel.: 604-875-2361 klausen@interchange.ubc.ca Klinck, Dr. Roscoe Universit de Sherbrooke Sherbrooke, QC Tel.: 819 820 6868 ext 15873 roscoe.klinck@usherbrooke.ca Kohn, Dr. Elise National Cancer Institute Bethesda, MD, USA Tel.: 301-402-2726 kohne@mail.nih.gov

Kortmann, Dr. Ursula BCCA Vancouver, BC Tel.: 604-733-6846 ukortmann@bccrc.ca Koti, Dr. Madhuri Queens University Kingston, ON Tel.: 613-533-2000 X 79055 madhurikoti@gmail.com Koushik, Dr. Anita University of Montral Montral, QC Tel.: 514-890-8000 X15915 anita.koushik@umontreal.ca Kulasingam, Dr. Vathany Mount Sinai Hospital Toronto, ON Tel.: 416-586-4800 X 7215 vathany.k@gmail.com Kussmann-Armstrong, Ms. Heidi The Armstrong Clinic Simcoe, ON Tel.: 519-426-4275 HEIDI@ARMSTRONGCLINIC.COM Kuzmanov, Mr. Uros University of Toronto Toronto, ON Tel.: 416-586-4800 X 8813 ukuzmanov@mtsinai.on.ca Lanner, Dr. Carita Northern Ontario School of Medicine Sudbury, ON Tel.: 705-662-7238 carita.lanner@normed.ca Le Page, Dr. Ccile CHUM Montral, QC Tel.: 514-890-8000 X 25491 cecilelepage@yahoo.ca

5th Canadian Conference on Ovarian Cancer Research

Lee, Dr. Jonathan University of Ottawa Ottawa, ON Tel.: 613-562-5800 X 8640 jlee@uottawa.ca Letarte, Dr. Michelle The Hospital for Sick Children Toronto, ON Tel.: 416-813-6258 michelle.letarte@sickkids.ca Madore, Mr. Jason Institut du cancer de Montral Montral, QC Tel.: 514-890-8000 X 24647 jason.madore@gmail.com Magliocco, Dr. Tony Tom Baker Cancer Centre Calgary, AB Tel.: 403-521-3073 magliocc@ucalgary.ca Mann, Mr. Vijay Roche - Canada Mississauga, ON Tel.: 905-542-5583 vijay.mann@roche.com Matte, Ms. Isabelle Universit de Sherbrooke St-Claude, QC Tel.: 819-845-5766 isabelle.matte@usherbrooke.ca McAlpine, Dr. Jessica UBC/BCCA Vancouver, BC Tel.: 604-877-6000 X 2367 jessica.mcalpine@vch.ca McLaughlin, Dr. John Cancer Care Ontario Toronto, ON Tel.: 416-971-9800 X 1234 john.mclaughlin@cancercare.on.ca

Medrano, Mr. Mauricio University of Toronto Toronto, ON Tel.: 647-500-8525 mauricio.medrano@utoronto.ca Mnard, Dr. Robert Biotechnology Research Institute - CNRC Montral, QC Tel.: 514-496-6317 robert.menard@cnrc-nrc.gc.ca Mendez-Herrera, Dr. Maria del Carmen UNAM Mxico, Mexico carmen2001@yahoo.com.mx Mes-Masson, Mrs. Anne-Marie Centre de recherche CHUM et Institut du cancer de Montral Montral, QC Tel.: 514-890-8000 X 25496
anne-marie.mes-masson@umontreal.ca

Meunier, Ms. Liliane CHUM Montral, QC Tel.: 514-890-8000 X 25491 liliane.meunier@gmail.com Meyniel, Dr. Jean-Philippe Institut Curie Hpital Saint-Louis Paris, France Tel.: +33-(0)1-53-19-41-26 jean-philippe.meyniel@curie.fr Milea, Ms. Anca Princess Margaret Hospital University of Toronto Toronto, ON Tel.: 647-208-1141 anca.milea@utoronto.ca Miller, Dr. Dianne Vancouver, BC Tel.: 604-875-4268 dianne.miller@vch.ca

Mok, Dr. Samuel M.D. Anderson Cancer Center Houston, TX, USA Tel.: 713-792-1442 scmok@mdanderson.org Mondragon-Huerta, Dr. Carmen UNAM Mxico, Mexico Tel.: +525556232264 car_gmh@yahoo.com.mx Moody, Dr. Joel Samuel Lunenfeld Research Institute Toronto, ON Tel.: 416-567-3776 moody@lunenfeld.ca Murphy, Dr. Joan University of Toronto Toronto, ON Tel.: 416-946-4043 joan.murphy@uhn.on.ca Nachtigal, Dr. Mark Dalhousie University Halifax, NS Tel.: 902-494-6348 mark.nachtigal@dal.ca Narod, Dr. Steven CRWH Toronto, ON Tel.: 416-351-3765 steven.narod@wchospital.ca Nelson, Dr. Brad BC Cancer Agency Victoria, BC Tel.: 250-519-5705 bnelson@bccancer.bc.ca Nwilati, Dr. Hanad Universit de Sherbrooke Sherbrooke, QC Tel.: 819-820-6868 X 12707 h.nwilati@usherbrooke.ca

www.ccocr2010.org

55

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

Ota, Dr. Takayo Mayo Clinic Rochester, MN, USA Tel.: 507-284-4516 takayo.ota@gmail.com Oza, Dr. Amit Princess Margaret Hospital Toronto, ON Tel.: 416.946.4501 X 2818 amit.oza@uhn.on.ca Peart, Ms. Teresa University of Western Ontario London, ON Tel.: 519-685-8500 tpeart@uwo.ca Peng, Dr. Chun York University Toronto, ON Tel.: 416-736-2100 X 40558 cpeng@yorku.ca Petrik, Dr. Jim University of Guelph Guelph, ON Tel.: 519-824-4120 X 54921 jpetrik@uoguelph.ca Pitre, Ms. Elizabeth University of Ottawa Ottawa, ON Tel.: 613-889-2225 elizabeth.pitre@gmail.com Prinos, Dr. Panagiotis Universit de Sherbrooke Sherbrooke, QC Tel.: 819-820-6868 panagiotis.Prinos@USherbrooke.ca Quinn, Dr. Michael McGill University Montral, QC Tel.: 514-934-1934 X 4033 michael.quinn@mail.mcgill.ca
56 Final Programme

Rafferty, Ms. Sara University of Ottawa Ottawa, ON Tel.: 613-296-9501 sara.a.rafferty@gmail.com Reed, Mr. Jason University of Western Ontario London, ON Tel.: 519-317-6063 jreed7@uwo.ca Robson, Mrs. Helen P. University of Toronto Toronto, ON Tel.: 416-729-9631 Helen.robson@utoronto.ca Ross, Dr. Elisabeth Ovarian Cancer Canada Toronto, ON Tel.: 877-413-7970 X 222 eross@ovariancanada.org Santos, Ms. Jennifer BC Cancer Agency Vancouver BC Tel.: 604-877-6000 X 2163 jsantos@bccancer.bc.ca Santos, Dr. Manuela CRCHUM/University of Montral Montral QC Tel.: 514-890-8000 X 28928 manuela.santos@umontreal.ca Schmandt, Dr. Rosemarie U.T. M.D. Anderson Cancer Center Houston, TX, USA Tel.: 713-745-1497 rschmand@mdanderson.org Selvamohan, Ms. Rosette Quebec, QC Tel.: 418-525-4444 rosette.sel@gmail.com

Shathasivam, Ms. Premalatha SLRI, Mount Sinai Hospital Toronto, ON Tel.: 416-586-4800 X 5601 shathasivam@lunenfeld.on.ca Shaw, Mr. Sanjeev UHN/CFIBCR Toronto, ON Tel.: 647-501-1977 sanjeev.shaw@uhnresearch.ca Shepherd, Dr. Trevor UWO London, ON Tel.: 519-685-8500 X 56347 tshephe6@uwo.ca Solangi, Dr. Humera Tawam Hospital Al Ain, United Arab Emirates Tel.: +97137513260 nisarsolangi53@hotmail.com Sommer, Dr. Nicolas Roche Canada (Hoffmann-La Roche Ltd.) Mississauga, ON Tel.: 905-542-5583 Nicolas.sommer@roche.com Sridaran, Prof. Rajagopala Morehouse School of Medecine Atlanta, GA, USA Tel.: 404-752-1684 rsridaran@msm.edu Steed, Dr. Helen University of Alberta Edmonton, AB Tel.: 780-432-8560
helen.steed@albertahealthservices.ca

Sugimoto, Dr. Akira London Health Sciences Centre / UWO London, ON Tel.: 519-685-8088 akira.sugimoto@lhsc.on.ca

5th Canadian Conference on Ovarian Cancer Research

Theriault, Dr. Brigitte Ontario Cancer Institute Toronto, ON Tel.: 416-946-4483 brigitte.theriault@uhnresearch.ca Tone, Dr. Alicia Toronto, ON Tel.: 416-586-4800 alicia.tone@utoronto.ca Tonin, Dr. Patricia McGill University Montral, QC Tel.: 514-934-1934 X 44069 patricia.tonin@mcgill.ca Tremblay, Dr. Gilles Alethia Biotherapeutics Montral, QC Tel.: 514-858-7666 gilles.tremblay@alethiabio.com Trudel, Dr. Dominique Centre Hospitalier Universitaire de Qubec Qubec, QC Tel.: 418-641-9114 dominique.trudel.3@ulaval.ca Tsang, Dr. Ben Ottawa Hospital Research Institute Ottawa, ON Tel.: 613-798-5555 X 16040 btsang@ohri.ca Vanderhyden, Prof. Barbara Ottawa Hospital Research Institute Ottawa, ON Tel.: 613-737-7700 X 70330 bvanderhyden@ohri.ca Weberpals, Dr. Johanne Ottawa Health Research Institute Ottawa, ON jweberpals@ottawahospital.on.ca

Welch, Dr. Stephen London Regional Cancer Program London, ON Tel.: 519-685-8640 stephen.welch@lhsc.on.ca Winegarden, Dr. Neil UHN Microarray Centre Toronto, ON Tel.: 416-581-7440 winegard@uhnresearch.ca Wojnarowicz, Ms. Paulina McGill University Montral, QC Tel.: 514-963-3696 paulina.wojnarowicz@mail.mcgill.ca Ye, Dr. Gang York University Toronto, ON Tel.: 416-736-2100 X 70428 gangye@yorku.ca Zietarska, Mrs. Magdalena Centre de recherche CHUM Montral, QC Tel.: 514-890-8000 X 25491 bmagda@yahoo.com

www.ccocr2010.org

57

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

My Notes

58

Final Programme

5th Canadian Conference on Ovarian Cancer Research

My Notes

www.ccocr2010.org

59

May 15-18, 2010 Hotel Delta Chelsea Inn Toronto, ON

My Notes

60

Final Programme

Time Breakfast (8:00-8:30)

Saturday, May 15

Schedule at a Glance
Sunday, May 16 Monday, May 17 Tuesday, May 18 Breakfast (8:00-8:30) Workshop for Trainees Part II (8:00-13:45) Lunch and Poster Session II (11:30-13:30) Registration (11:00-17:00) Symposium II: Etiology and Prevention - Cells of Origin and Stem Cells (8:30-11:30) Symposium IV: Targeted Therapies and Current and Emergent Clinical Trials (8:30-11:15)

am

Survivor Workshop (9:15-16:30)

Lunch and Poster Session III (11:15-13:30)

pm

Workshop for Trainees - Part 1 (12:00-18:00)

Symposium III: Models of Ovarian Cancer for Mechanistic and Therapeutic Studies (13:30-16:30)

Workshop II (13:30-15:30)

Welcome Remarks / Symposium I Genomics and Proteomics in the Discovery of Novel Biomarkers and Therapies (14:00-17:00)

Workshop I (16:30-18:00)

Reports, Summary, Awards and Farewell (15:30-17:00)

Evening

Informal evening for trainees (18:00)

Opening Reception and Poster Session I (17:00-20:00) Social Event (19:00)

ConferenCe SeCretariat c/o IS Event Solutions


1334 Notre-Dame Street West, 2nd Floor Montral, Qubec, Canada H3C 1K7 Tel.: Fax: (514) 392-7703 (514) 227-5083

E-mail: info@iseventsolutions.com www.ccocr2010.org

Printed in Canada May 2010

You might also like